US20160297761A1 - Novel inhibitors of glutaminase - Google Patents
Novel inhibitors of glutaminase Download PDFInfo
- Publication number
- US20160297761A1 US20160297761A1 US14/769,365 US201514769365A US2016297761A1 US 20160297761 A1 US20160297761 A1 US 20160297761A1 US 201514769365 A US201514769365 A US 201514769365A US 2016297761 A1 US2016297761 A1 US 2016297761A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- unsubstituted
- pyridin
- compound
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]P**BC[2*] Chemical compound [1*]P**BC[2*] 0.000 description 36
- JXQGICFGPUAVLJ-UHFFFAOYSA-N Cc1nnc(C)[s]1 Chemical compound Cc1nnc(C)[s]1 JXQGICFGPUAVLJ-UHFFFAOYSA-N 0.000 description 26
- VRUFOFGUERADFX-UHFFFAOYSA-N CC1=CC=C(C)N=N1.CC1=NN=C(C)S1 Chemical compound CC1=CC=C(C)N=N1.CC1=NN=C(C)S1 VRUFOFGUERADFX-UHFFFAOYSA-N 0.000 description 16
- TXVMPTUVBKETKZ-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1 Chemical compound CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1 TXVMPTUVBKETKZ-UHFFFAOYSA-N 0.000 description 12
- KDGWEQUITVDCSM-UHFFFAOYSA-N CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1.CC1=CN(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1.CC1=NN=C(C)S1 Chemical compound CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1.CC1=CN(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1.CC1=NN=C(C)S1 KDGWEQUITVDCSM-UHFFFAOYSA-N 0.000 description 10
- OKPCMSDLDVUCEF-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1 Chemical compound CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1 OKPCMSDLDVUCEF-UHFFFAOYSA-N 0.000 description 9
- BHVMZIRBEIMNAB-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1 Chemical compound CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1 BHVMZIRBEIMNAB-UHFFFAOYSA-N 0.000 description 9
- XWXULBBRFBOZOJ-UHFFFAOYSA-N CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1 Chemical compound CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1 XWXULBBRFBOZOJ-UHFFFAOYSA-N 0.000 description 8
- NFKLRQUJHKZJCU-UHFFFAOYSA-N CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1 Chemical compound CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1 NFKLRQUJHKZJCU-UHFFFAOYSA-N 0.000 description 6
- GVBXHTCVVDWREE-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1 Chemical compound CC1=CC=C(C)C(F)=N1 GVBXHTCVVDWREE-UHFFFAOYSA-N 0.000 description 5
- QOVSLNANYHOYDK-UHFFFAOYSA-N CC1=CN(C)N=N1.CC1=CN=C(C)N1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1 Chemical compound CC1=CN(C)N=N1.CC1=CN=C(C)N1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1 QOVSLNANYHOYDK-UHFFFAOYSA-N 0.000 description 5
- BGVTUIRPHLSMJU-UHFFFAOYSA-N Cc1ccc(C)nn1 Chemical compound Cc1ccc(C)nn1 BGVTUIRPHLSMJU-UHFFFAOYSA-N 0.000 description 5
- FRCVJHRPSCOSQS-UHFFFAOYSA-N CC1=CC=C(C)C(C)=N1.CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1 Chemical compound CC1=CC=C(C)C(C)=N1.CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1 FRCVJHRPSCOSQS-UHFFFAOYSA-N 0.000 description 4
- MGVSDZLMOXPKFZ-UHFFFAOYSA-N CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1 Chemical compound CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1 MGVSDZLMOXPKFZ-UHFFFAOYSA-N 0.000 description 4
- KSVZBGUQJNFMRP-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1.CC1=NN=C(C)S1 Chemical compound CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1.CC1=NN=C(C)S1 KSVZBGUQJNFMRP-UHFFFAOYSA-N 0.000 description 4
- WVUHHPQQQLBMOE-UHFFFAOYSA-N CC1=CN=C(C)S1 Chemical compound CC1=CN=C(C)S1 WVUHHPQQQLBMOE-UHFFFAOYSA-N 0.000 description 4
- XEDLSXDSHPMJPB-UHFFFAOYSA-N CC1C(C)(C)C(C)(C)C(C)C(C)(C)C1(C)C Chemical compound CC1C(C)(C)C(C)(C)C(C)C(C)(C)C1(C)C XEDLSXDSHPMJPB-UHFFFAOYSA-N 0.000 description 4
- XYVVSNUIMTZLSO-UHFFFAOYSA-N CC1=C(C(F)(F)F)C=CC(Cl)=C1.CC1=C(C)C=CC=C1.CC1=C(F)C(F)=CC=C1.CC1=C(F)C(F)=CC=C1F.CC1=C(OC(F)(F)F)N=C(NS(C)(=O)=O)C=C1.CC1=C(OC(F)(F)F)N=CC=C1.CC1=CC(C#N)=CC=C1.CC1=CC(C(F)(F)F)=NN1C.CC1=CC(F)=C(F)C=C1.CC1=CC(N2CC(F)C2)=CC=C1.CC1=CC(N2CCC2)=CC=C1.CC1=CC=C(Cl)C=C1.CC1=CC=C(F)C=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CN=C(NS(C)(=O)=O)C=C1.CC1=CNC2=C1C=CC=C2.CC1=NC(OC(F)(F)F)=C(NS(C)(=O)=O)C=C1.CC1=NC(OC(F)(F)F)=CC=C1.CC1=NC=C(NS(C)(=O)=O)C=C1.CC1=NC=CN=C1.CN1C=CC=N1.COC1=C(C)C=CC(NS(C)(=O)=O)=N1.COC1=C(C)C=CC=N1.COC1=C(NS(C)(=O)=O)C=CC(C)=N1 Chemical compound CC1=C(C(F)(F)F)C=CC(Cl)=C1.CC1=C(C)C=CC=C1.CC1=C(F)C(F)=CC=C1.CC1=C(F)C(F)=CC=C1F.CC1=C(OC(F)(F)F)N=C(NS(C)(=O)=O)C=C1.CC1=C(OC(F)(F)F)N=CC=C1.CC1=CC(C#N)=CC=C1.CC1=CC(C(F)(F)F)=NN1C.CC1=CC(F)=C(F)C=C1.CC1=CC(N2CC(F)C2)=CC=C1.CC1=CC(N2CCC2)=CC=C1.CC1=CC=C(Cl)C=C1.CC1=CC=C(F)C=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CN=C(NS(C)(=O)=O)C=C1.CC1=CNC2=C1C=CC=C2.CC1=NC(OC(F)(F)F)=C(NS(C)(=O)=O)C=C1.CC1=NC(OC(F)(F)F)=CC=C1.CC1=NC=C(NS(C)(=O)=O)C=C1.CC1=NC=CN=C1.CN1C=CC=N1.COC1=C(C)C=CC(NS(C)(=O)=O)=N1.COC1=C(C)C=CC=N1.COC1=C(NS(C)(=O)=O)C=CC(C)=N1 XYVVSNUIMTZLSO-UHFFFAOYSA-N 0.000 description 3
- FKMBUIZSAYLYPC-UHFFFAOYSA-N CC1=C(C)N=CC=C1.CC1=C(Cl)C=CC=C1.CC1=C(F)C=CC=C1.CC1=C(OC(F)(F)F)C=CC=C1.CC1=CC(Cl)=CC=C1.CC1=CC(F)=CC=C1.CC1=CC(NS(C)(=O)=O)=C(OC(F)(F)F)C=C1.CC1=CC(NS(C)(=O)=O)=CC=C1.CC1=CC(OC(F)(F)F)=C(NS(C)(=O)=O)C=C1.CC1=CC(OC(F)(F)F)=CC=C1.CC1=CC(S(C)(=O)=O)=CC=C1.CC1=CC=C(C2CCN(C(=O)OC(C)(C)C)CC2)C=C1.CC1=CC=C(C2CCNCC2)C=C1.CC1=CC=C(F)C(C)=N1.CC1=CC=C(NS(C)(=O)=O)C=C1.CC1=CC=C(OC(F)(F)F)C=C1.CC1=CC=C(S(C)(=O)=O)C=C1.CC1=CC=CC(C)=N1.CC1=CC=CC=C1.CC1=CC=NC=C1.CC1=CN=CC=C1.CC1=NC(OC(F)(F)F)=CC=C1.CC1=NC=CC=C1.COC1=C(C)C=CC=C1.COC1=C(NS(C)(=O)=O)C=C(C)C=C1.COC1=C(NS(C)(=O)=O)C=CC(C)=C1.COC1=CC=C(C)C=C1.COC1=CC=CC(C)=C1 Chemical compound CC1=C(C)N=CC=C1.CC1=C(Cl)C=CC=C1.CC1=C(F)C=CC=C1.CC1=C(OC(F)(F)F)C=CC=C1.CC1=CC(Cl)=CC=C1.CC1=CC(F)=CC=C1.CC1=CC(NS(C)(=O)=O)=C(OC(F)(F)F)C=C1.CC1=CC(NS(C)(=O)=O)=CC=C1.CC1=CC(OC(F)(F)F)=C(NS(C)(=O)=O)C=C1.CC1=CC(OC(F)(F)F)=CC=C1.CC1=CC(S(C)(=O)=O)=CC=C1.CC1=CC=C(C2CCN(C(=O)OC(C)(C)C)CC2)C=C1.CC1=CC=C(C2CCNCC2)C=C1.CC1=CC=C(F)C(C)=N1.CC1=CC=C(NS(C)(=O)=O)C=C1.CC1=CC=C(OC(F)(F)F)C=C1.CC1=CC=C(S(C)(=O)=O)C=C1.CC1=CC=CC(C)=N1.CC1=CC=CC=C1.CC1=CC=NC=C1.CC1=CN=CC=C1.CC1=NC(OC(F)(F)F)=CC=C1.CC1=NC=CC=C1.COC1=C(C)C=CC=C1.COC1=C(NS(C)(=O)=O)C=C(C)C=C1.COC1=C(NS(C)(=O)=O)C=CC(C)=C1.COC1=CC=C(C)C=C1.COC1=CC=CC(C)=C1 FKMBUIZSAYLYPC-UHFFFAOYSA-N 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N CC1=CC=C(C)N=C1 Chemical compound CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
- JJPLKWPDNVVKOV-UHFFFAOYSA-N CC1=CN=C(C)N1.CC1=CN=C(C)S1.CC1=NC(C)N=N1.CC1=NN(C)C=N1.CC1=NN=C(C)N1 Chemical compound CC1=CN=C(C)N1.CC1=CN=C(C)S1.CC1=NC(C)N=N1.CC1=NN(C)C=N1.CC1=NN=C(C)N1 JJPLKWPDNVVKOV-UHFFFAOYSA-N 0.000 description 3
- LKRZPUQBFSLMHN-UHFFFAOYSA-N N#CCCCCC1=CN=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 Chemical compound N#CCCCCC1=CN=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 LKRZPUQBFSLMHN-UHFFFAOYSA-N 0.000 description 3
- NOJPLBITJFIHBY-UHFFFAOYSA-N CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1 Chemical compound CC1=CC=C(C)C(F)=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1 NOJPLBITJFIHBY-UHFFFAOYSA-N 0.000 description 2
- XDCPPHVPLURRGF-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1 Chemical compound CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=N1 XDCPPHVPLURRGF-UHFFFAOYSA-N 0.000 description 2
- BMMZQDNVCIYKDR-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=N1.CC1=CN(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1.CC1=NN=C(C)S1 Chemical compound CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=N1.CC1=CN(C)N=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)S1.CC1=NN(C)C=N1.CC1=NN=C(C)N1.CC1=NN=C(C)S1 BMMZQDNVCIYKDR-UHFFFAOYSA-N 0.000 description 2
- NWYAYZDTKWWCBC-UHFFFAOYSA-N CC1CC(C)C1.CC1CC1C.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1 Chemical compound CC1CC(C)C1.CC1CC1C.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1 NWYAYZDTKWWCBC-UHFFFAOYSA-N 0.000 description 2
- WLJRWZVPUAMWII-UHFFFAOYSA-N CC1CC(C)C1.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1 Chemical compound CC1CC(C)C1.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1 WLJRWZVPUAMWII-UHFFFAOYSA-N 0.000 description 2
- QRZWELWKHFJSEE-UHFFFAOYSA-N CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CC(C)C1.CCC1CC1CC.CCC1CCC(C)C1.CCC1CCCC(C)C1 Chemical compound CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CC(C)C1.CCC1CC1CC.CCC1CCC(C)C1.CCC1CCCC(C)C1 QRZWELWKHFJSEE-UHFFFAOYSA-N 0.000 description 2
- SLNSMQFJBMAWIC-UHFFFAOYSA-N CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CC(C)C1.CCC1CCC(C)C1.CCC1CCCC(C)C1 Chemical compound CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CC(C)C1.CCC1CCC(C)C1.CCC1CCCC(C)C1 SLNSMQFJBMAWIC-UHFFFAOYSA-N 0.000 description 2
- LVXHUQABWLTQND-UHFFFAOYSA-N CCC1CC(C)C1 Chemical compound CCC1CC(C)C1 LVXHUQABWLTQND-UHFFFAOYSA-N 0.000 description 2
- IQYGMPMFXYKNJT-UHFFFAOYSA-N COC1=CC=CC=C1CC(=O)NC1=NN=C(CCC#CC2=CC=C(NC(=O)CC3=CC=CC=C3Cl)N=C2)S1 Chemical compound COC1=CC=CC=C1CC(=O)NC1=NN=C(CCC#CC2=CC=C(NC(=O)CC3=CC=CC=C3Cl)N=C2)S1 IQYGMPMFXYKNJT-UHFFFAOYSA-N 0.000 description 2
- LCZUOKDVTBMCMX-UHFFFAOYSA-N Cc1cnc(C)cn1 Chemical compound Cc1cnc(C)cn1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 2
- RHOOLJLEYYXKTK-UHFFFAOYSA-N Cc1cnc(C)nc1 Chemical compound Cc1cnc(C)nc1 RHOOLJLEYYXKTK-UHFFFAOYSA-N 0.000 description 2
- CHGUIGVDLAZCCZ-UHFFFAOYSA-N Cl.O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC(C4CCNCC4)=CC=C3)S2)C=C1 Chemical compound Cl.O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC(C4CCNCC4)=CC=C3)S2)C=C1 CHGUIGVDLAZCCZ-UHFFFAOYSA-N 0.000 description 2
- LZOYKHQOLKCGFG-UHFFFAOYSA-N NC1=NN=C(C2CC(CC3=CC=C(NC(=O)CC4=CC=CN=C4)N=C3)C2)S1 Chemical compound NC1=NN=C(C2CC(CC3=CC=C(NC(=O)CC4=CC=CN=C4)N=C3)C2)S1 LZOYKHQOLKCGFG-UHFFFAOYSA-N 0.000 description 2
- NGGJWHRHXQHWAX-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CC=N4)S3)C2)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CC=N4)S3)C2)C=C1 NGGJWHRHXQHWAX-UHFFFAOYSA-N 0.000 description 2
- HIVCJAPLYMMMKN-UHFFFAOYSA-N O=C(CC1=CC=CC=C1)NC1=NN=C(C2CCC(C3=NN=C(NC(=O)CC4=CC=CC=C4)S3)CC2)S1 Chemical compound O=C(CC1=CC=CC=C1)NC1=NN=C(C2CCC(C3=NN=C(NC(=O)CC4=CC=CC=C4)S3)CC2)S1 HIVCJAPLYMMMKN-UHFFFAOYSA-N 0.000 description 2
- SQNXRUDHOVXRRZ-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=C3)S2)C=N1 SQNXRUDHOVXRRZ-UHFFFAOYSA-N 0.000 description 2
- XUBPBDQORJDLFE-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=NC=C(CC2CC(C3=NN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)S3)C2)C=C1 Chemical compound O=C(CC1=CC=CN=C1)NC1=NC=C(CC2CC(C3=NN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)S3)C2)C=C1 XUBPBDQORJDLFE-UHFFFAOYSA-N 0.000 description 2
- WIUJNAQMFZJEED-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=NN=C(C2CCC(C3=NN=C(NC(=O)CC4=CN=CC=C4)S3)CC2)S1 Chemical compound O=C(CC1=CC=CN=C1)NC1=NN=C(C2CCC(C3=NN=C(NC(=O)CC4=CN=CC=C4)S3)CC2)S1 WIUJNAQMFZJEED-UHFFFAOYSA-N 0.000 description 2
- MYALOPJJAPLQSJ-UHFFFAOYSA-N BrCC1CCC(CBr)CC1 Chemical compound BrCC1CCC(CBr)CC1 MYALOPJJAPLQSJ-UHFFFAOYSA-N 0.000 description 1
- ADRQSFLYTSEGBQ-UHFFFAOYSA-N C#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 Chemical compound C#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 ADRQSFLYTSEGBQ-UHFFFAOYSA-N 0.000 description 1
- GTHGIWGHIZCRBY-UHFFFAOYSA-N C#CC1=CN=C(NC(=O)CC2=CC=CC(C)=C2)C=C1.C#C[Si](C)(C)C.CC1=CC(CC(=O)NC2=NC=C(Br)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(C#C[Si](C)(C)C)C=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.NC1=NC=C(Br)C=C1 Chemical compound C#CC1=CN=C(NC(=O)CC2=CC=CC(C)=C2)C=C1.C#C[Si](C)(C)C.CC1=CC(CC(=O)NC2=NC=C(Br)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(C#C[Si](C)(C)C)C=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.NC1=NC=C(Br)C=C1 GTHGIWGHIZCRBY-UHFFFAOYSA-N 0.000 description 1
- MPUSPXNUXBQTBK-UHFFFAOYSA-N C#CC1=CN=C(NC(=O)CC2=CC=CC(C)=C2)C=C1.CC1=CC(CC(=O)NC2=CC=C(C#CC#CC3=CN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)C=C3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CCCCC3=CN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)C=C3)C=N2)=CC=C1 Chemical compound C#CC1=CN=C(NC(=O)CC2=CC=CC(C)=C2)C=C1.CC1=CC(CC(=O)NC2=CC=C(C#CC#CC3=CN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)C=C3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CCCCC3=CN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)C=C3)C=N2)=CC=C1 MPUSPXNUXBQTBK-UHFFFAOYSA-N 0.000 description 1
- UEIQYFTUGRJXKZ-UHFFFAOYSA-N C#CCCBr.NBBr.NBC#CCCBr.NBC#CCCBr[Zn] Chemical compound C#CCCBr.NBBr.NBC#CCCBr.NBC#CCCBr[Zn] UEIQYFTUGRJXKZ-UHFFFAOYSA-N 0.000 description 1
- AXRCVXQJKBVZRJ-UHFFFAOYSA-N C#CCCBr.NC1=NC=C(Br)C=C1.NC1=NC=C(C#CCCBr)C=C1.NC1=NC=C(C#CCCBr[Zn])C=C1 Chemical compound C#CCCBr.NC1=NC=C(Br)C=C1.NC1=NC=C(C#CCCBr)C=C1.NC1=NC=C(C#CCCBr[Zn])C=C1 AXRCVXQJKBVZRJ-UHFFFAOYSA-N 0.000 description 1
- CFKYJILEQMZFCP-UHFFFAOYSA-N C#CCCC#N.CC1=CC(CC(=O)NC2=NC(F)=C(Br)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(C#CCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.NC1=NC(F)=C(Br)C=C1 Chemical compound C#CCCC#N.CC1=CC(CC(=O)NC2=NC(F)=C(Br)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(C#CCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.NC1=NC(F)=C(Br)C=C1 CFKYJILEQMZFCP-UHFFFAOYSA-N 0.000 description 1
- ONIBYXJTHRNMOK-UHFFFAOYSA-N C#CCCC#N.CC1=CC(CC(=O)NC2=NC=C(CCCCC#N)N=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.N#CCCC#CC1=NC=C(N)N=C1.N#CCCCCC1=NC=C(N)N=C1.NC1=NC=C(Br)N=C1 Chemical compound C#CCCC#N.CC1=CC(CC(=O)NC2=NC=C(CCCCC#N)N=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.N#CCCC#CC1=NC=C(N)N=C1.N#CCCCCC1=NC=C(N)N=C1.NC1=NC=C(Br)N=C1 ONIBYXJTHRNMOK-UHFFFAOYSA-N 0.000 description 1
- PIXGMZOQRQMMLM-XXYIHWIKSA-N C=C1CC(C#N)C1.CC1=CC(CC(=O)NC2=NC=C(C=C3CC(C#N)C3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CC3CC(C#N)C3)C=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.N#CC1CC(=CC2=CC=C(N)N=C2)C1.NC1=NC=C(Br)C=C1 Chemical compound C=C1CC(C#N)C1.CC1=CC(CC(=O)NC2=NC=C(C=C3CC(C#N)C3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CC3CC(C#N)C3)C=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.N#CC1CC(=CC2=CC=C(N)N=C2)C1.NC1=NC=C(Br)C=C1 PIXGMZOQRQMMLM-XXYIHWIKSA-N 0.000 description 1
- YEGSCOOGJWVWNQ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(C2=CC=C(CC(=O)NC3=NN=C(CCCCC4=CN=C(NC(=O)CC5=CC=CC(OC(F)(F)F)=C5)C=C4)S3)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(C2=CC=C(CC(=O)NC3=NN=C(CCCCC4=CN=C(NC(=O)CC5=CC=CC(OC(F)(F)F)=C5)C=C4)S3)C=C2)CC1 YEGSCOOGJWVWNQ-UHFFFAOYSA-N 0.000 description 1
- WLJIBNDZSWXABP-UHFFFAOYSA-N CC(Cl)C(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 Chemical compound CC(Cl)C(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 WLJIBNDZSWXABP-UHFFFAOYSA-N 0.000 description 1
- YZOMPOFVCJUITH-UHFFFAOYSA-N CC1=CC(CC(=O)CC2=CN=C(CC3CC(C4=NN=C(NC(=O)CC5=NC=CC=C5)S4)C3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CC3CC(C(=O)O)C3)N=C2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CC3CC(C4=NN=C(N)S4)C3)N=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=CC=CC=N1 Chemical compound CC1=CC(CC(=O)CC2=CN=C(CC3CC(C4=NN=C(NC(=O)CC5=NC=CC=C5)S4)C3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CC3CC(C(=O)O)C3)N=C2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CC3CC(C4=NN=C(N)S4)C3)N=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=CC=CC=N1 YZOMPOFVCJUITH-UHFFFAOYSA-N 0.000 description 1
- RUQHPAKQQMKHOA-UHFFFAOYSA-N CC1=CC(CC(=O)NC2=CC=C(C#CCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CCCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(C#CCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(C#CCCC3=NN=C(N)S3)C=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=NC=CC=C1 Chemical compound CC1=CC(CC(=O)NC2=CC=C(C#CCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=CC=C(CCCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(C#CCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(C#CCCC3=NN=C(N)S3)C=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=NC=CC=C1 RUQHPAKQQMKHOA-UHFFFAOYSA-N 0.000 description 1
- HNNWVKHYLAMNAI-UHFFFAOYSA-N CC1=CC(CC(=O)NC2=CC=C(CC3CC(C(=O)O)C3)N=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.NC1=CC=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)N=C1.NC1=CC=C(Cl)N=C1.O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)N=C1.O=C(OCC1=CC=CC=C1)C1CC(CBr)C1.O=C(OCC1=CC=CC=C1)C1CC(CO)C1 Chemical compound CC1=CC(CC(=O)NC2=CC=C(CC3CC(C(=O)O)C3)N=C2)=CC=C1.CC1=CC(CC(=O)O)=CC=C1.NC1=CC=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)N=C1.NC1=CC=C(Cl)N=C1.O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)N=C1.O=C(OCC1=CC=CC=C1)C1CC(CBr)C1.O=C(OCC1=CC=CC=C1)C1CC(CO)C1 HNNWVKHYLAMNAI-UHFFFAOYSA-N 0.000 description 1
- WLZNSMNBHUQAKJ-UHFFFAOYSA-N CC1=CC(CC(=O)NC2=CN=C(CCCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CCCCC#N)N=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CCCCC3=NN=C(N)S3)N=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=NC=CC=C1.[H]Cl Chemical compound CC1=CC(CC(=O)NC2=CN=C(CCCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=N2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CCCCC#N)N=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CCCCC3=NN=C(N)S3)N=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=NC=CC=C1.[H]Cl WLZNSMNBHUQAKJ-UHFFFAOYSA-N 0.000 description 1
- OOEAASSEJWTYQD-UHFFFAOYSA-N CC1=CC(CC(=O)NC2=NC(F)=C(C#CCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(CCCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(CCCCC3=NN=C(N)S3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(CCCCC3=NN=C(NC(=O)CC4=CC=CN=C4)S3)C=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=CC=CN=C1 Chemical compound CC1=CC(CC(=O)NC2=NC(F)=C(C#CCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(CCCCC#N)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(CCCCC3=NN=C(N)S3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC(F)=C(CCCCC3=NN=C(NC(=O)CC4=CC=CN=C4)S3)C=C2)=CC=C1.NNC(N)=S.O=C(O)CC1=CC=CN=C1 OOEAASSEJWTYQD-UHFFFAOYSA-N 0.000 description 1
- IHMSISWBULFDOU-UHFFFAOYSA-N CC1=CC(CC(=O)NC2=NC=C(CC3CC(C#N)C3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CC3CC(C4=NN=C(N)S4)C3)C=C2)=CC=C1.NNC(N)=S.O=C(CC1=CC=CC(OC(F)(F)F)=C1)CC1=CC=C(CC2CC(C3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C2)C=N1.O=C(O)CC1=CC=CC=N1 Chemical compound CC1=CC(CC(=O)NC2=NC=C(CC3CC(C#N)C3)C=C2)=CC=C1.CC1=CC(CC(=O)NC2=NC=C(CC3CC(C4=NN=C(N)S4)C3)C=C2)=CC=C1.NNC(N)=S.O=C(CC1=CC=CC(OC(F)(F)F)=C1)CC1=CC=C(CC2CC(C3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C2)C=N1.O=C(O)CC1=CC=CC=N1 IHMSISWBULFDOU-UHFFFAOYSA-N 0.000 description 1
- LEBWKDCBYZCVGP-UHFFFAOYSA-N CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=N1 Chemical compound CC1=CC=C(C)C(F)=N1.CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=N1 LEBWKDCBYZCVGP-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N CC1=CC=C(C)C=C1 Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- ITDIFEZKZSZTHV-UHFFFAOYSA-N CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)N=C1 Chemical compound CC1=CC=C(C)N=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)N=C1 ITDIFEZKZSZTHV-UHFFFAOYSA-N 0.000 description 1
- IRMOYHVMRRTBJJ-UHFFFAOYSA-N CC1=CC=C(C)NN1 Chemical compound CC1=CC=C(C)NN1 IRMOYHVMRRTBJJ-UHFFFAOYSA-N 0.000 description 1
- FVWBBCJXXCAOEE-UHFFFAOYSA-M CC1=CC=CC=C1CC(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=C(Cl)C=CC=C3)C=N2)S1.COC1=C(CC(=O)O)C=CC=C1.N#CCCCC[Zn]Br.NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=C(Cl)C=CC=C3)C=N2)S1.NNC(N)=S.O=C(CC1=C(Cl)C=CC=C1)NC1=CN=C(Cl)C=C1.[C-]#[N+]CCCCC1=NC=C(NC(=O)CC2=C(Cl)C=CC=C2)C=C1 Chemical compound CC1=CC=CC=C1CC(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=C(Cl)C=CC=C3)C=N2)S1.COC1=C(CC(=O)O)C=CC=C1.N#CCCCC[Zn]Br.NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=C(Cl)C=CC=C3)C=N2)S1.NNC(N)=S.O=C(CC1=C(Cl)C=CC=C1)NC1=CN=C(Cl)C=C1.[C-]#[N+]CCCCC1=NC=C(NC(=O)CC2=C(Cl)C=CC=C2)C=C1 FVWBBCJXXCAOEE-UHFFFAOYSA-M 0.000 description 1
- WSASDOWJTRCKGM-UHFFFAOYSA-N CC1=NC(C(=O)NC2=NN=C(CCCCC3=CN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)=C(F)C=C1 Chemical compound CC1=NC(C(=O)NC2=NN=C(CCCCC3=CN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)=C(F)C=C1 WSASDOWJTRCKGM-UHFFFAOYSA-N 0.000 description 1
- SPYTXEXTNMZYDB-UHFFFAOYSA-N CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1Br Chemical compound CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1Br SPYTXEXTNMZYDB-UHFFFAOYSA-N 0.000 description 1
- GKNBPIBASNCKMK-UHFFFAOYSA-N CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1C#CCCC#N Chemical compound CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1C#CCCC#N GKNBPIBASNCKMK-UHFFFAOYSA-N 0.000 description 1
- XGSAANGGWLUALX-UHFFFAOYSA-N CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1CCCCC#N Chemical compound CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1CCCCC#N XGSAANGGWLUALX-UHFFFAOYSA-N 0.000 description 1
- WKSOLDFHCJOFEY-UHFFFAOYSA-N CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1CCCCC1=NN=C(N)S1 Chemical compound CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1CCCCC1=NN=C(N)S1 WKSOLDFHCJOFEY-UHFFFAOYSA-N 0.000 description 1
- FXDUWWLDDWHLIW-UHFFFAOYSA-N CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1CCCCC1=NN=C(NC(=O)CC2=CC=CC=N2)S1 Chemical compound CC1=NC(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)=CC=C1CCCCC1=NN=C(NC(=O)CC2=CC=CC=N2)S1 FXDUWWLDDWHLIW-UHFFFAOYSA-N 0.000 description 1
- CEBXDIKETRTFKB-UHFFFAOYSA-N CC1CC(C)C1.CC1CC1C.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CC(C)C1.CCC1CC(C)C1.CCC1CC(CC)C1.CCC1CC1C.CCC1CC1C.CCC1CC1CC.CCC1CCC(C)C1.CCC1CCC(C)C1.CCC1CCC(C)CC1.CCC1CCC(C)CC1.CCC1CCC(CC)C1.CCC1CCC(CC)CC1.CCC1CCCC(C)C1.CCC1CCCC(C)C1.CCC1CCCC(CC)C1 Chemical compound CC1CC(C)C1.CC1CC1C.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CC(C)C1.CCC1CC(C)C1.CCC1CC(CC)C1.CCC1CC1C.CCC1CC1C.CCC1CC1CC.CCC1CCC(C)C1.CCC1CCC(C)C1.CCC1CCC(C)CC1.CCC1CCC(C)CC1.CCC1CCC(CC)C1.CCC1CCC(CC)CC1.CCC1CCCC(C)C1.CCC1CCCC(C)C1.CCC1CCCC(CC)C1 CEBXDIKETRTFKB-UHFFFAOYSA-N 0.000 description 1
- FTTXYFXONNYHEL-UHFFFAOYSA-N CC1CC(C)C1.CC1CC1C.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CCC1CC(C)C1.CCC1CC(C)C1.CCC1CC(CC)C1.CCC1CC1C.CCC1CC1C.CCC1CC1CC.CCC1CCC(CC)C1 Chemical compound CC1CC(C)C1.CC1CC1C.CC1CC2CCC1C(C)C2.CC1CC2CCC1CC2C.CCC1CC(C)C1.CCC1CC(C)C1.CCC1CC(CC)C1.CCC1CC1C.CCC1CC1C.CCC1CC1CC.CCC1CCC(CC)C1 FTTXYFXONNYHEL-UHFFFAOYSA-N 0.000 description 1
- NSHIPMHKZIGUKE-UHFFFAOYSA-N CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CCC(C)C1.CCC1CCC(C)C1.CCC1CCC(C)CC1.CCC1CCC(C)CC1.CCC1CCC(CC)CC1.CCC1CCCC(C)C1.CCC1CCCC(C)C1.CCC1CCCC(CC)C1 Chemical compound CC1CCC(C)C1.CC1CCC(C)CC1.CC1CCCC(C)C1.CCC1CCC(C)C1.CCC1CCC(C)C1.CCC1CCC(C)CC1.CCC1CCC(C)CC1.CCC1CCC(CC)CC1.CCC1CCCC(C)C1.CCC1CCCC(C)C1.CCC1CCCC(CC)C1 NSHIPMHKZIGUKE-UHFFFAOYSA-N 0.000 description 1
- IYTWLEQVRFBBFO-UHFFFAOYSA-N CCC(Cl)C(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 Chemical compound CCC(Cl)C(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 IYTWLEQVRFBBFO-UHFFFAOYSA-N 0.000 description 1
- FTUKECANCNBBSR-UHFFFAOYSA-N CCC1CC(C)C1.CCC1CC(C)C1 Chemical compound CCC1CC(C)C1.CCC1CC(C)C1 FTUKECANCNBBSR-UHFFFAOYSA-N 0.000 description 1
- PBTANPUTIXIOAX-UHFFFAOYSA-N COC1=CC=CC=C1CC(=O)NC1=CN=C(Br)S1.COC1=CC=CC=C1CC(=O)NC1=CN=C(CC#CCC2=CN=C(N)C=C2)S1.COC1=CC=CC=C1CC(=O)NC1=CN=C(CCCCC2=CN=C(N)C=C2)S1.COC1=CC=CC=C1CC(=O)NC1=CN=C(CCCCC2=CN=C(NC(=O)CC3=C(Cl)C=CC=C3)C=C2)S1.NC1=NC=C(C#CCCBr[Zn])C=C1.O=C(O)CC1=C(Cl)C=CC=C1 Chemical compound COC1=CC=CC=C1CC(=O)NC1=CN=C(Br)S1.COC1=CC=CC=C1CC(=O)NC1=CN=C(CC#CCC2=CN=C(N)C=C2)S1.COC1=CC=CC=C1CC(=O)NC1=CN=C(CCCCC2=CN=C(N)C=C2)S1.COC1=CC=CC=C1CC(=O)NC1=CN=C(CCCCC2=CN=C(NC(=O)CC3=C(Cl)C=CC=C3)C=C2)S1.NC1=NC=C(C#CCCBr[Zn])C=C1.O=C(O)CC1=C(Cl)C=CC=C1 PBTANPUTIXIOAX-UHFFFAOYSA-N 0.000 description 1
- JSBZWZVKYHBXDE-UHFFFAOYSA-N COC1=CC=CC=C1CC(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC=C3Cl)N=C2)S1 Chemical compound COC1=CC=CC=C1CC(=O)NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC=C3Cl)N=C2)S1 JSBZWZVKYHBXDE-UHFFFAOYSA-N 0.000 description 1
- CDIZKFMPETVEIQ-UHFFFAOYSA-N CS(=O)(=O)C1=CC=C(CC(=O)NC2=NN=C(CCCCC3=CC=C(NC(=O)CC4=CC=CN=C4)N=C3)S2)C=C1 Chemical compound CS(=O)(=O)C1=CC=C(CC(=O)NC2=NN=C(CCCCC3=CC=C(NC(=O)CC4=CC=CN=C4)N=C3)S2)C=C1 CDIZKFMPETVEIQ-UHFFFAOYSA-N 0.000 description 1
- WWXYVXLANRNGIM-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(CC(=O)NC2=NN=C(CCCCC3=CC=C(NC(=O)CC4=CC=CN=C4)N=C3)S2)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(CC(=O)NC2=NN=C(CCCCC3=CC=C(NC(=O)CC4=CC=CN=C4)N=C3)S2)=C1 WWXYVXLANRNGIM-UHFFFAOYSA-N 0.000 description 1
- OOSWMBBSRRRIQH-UHFFFAOYSA-N CS(=O)(=O)NC1=CC(CC(=O)NC2=NN=C(CCCCC3=C(F)N=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)=CC=C1 Chemical compound CS(=O)(=O)NC1=CC(CC(=O)NC2=NN=C(CCCCC3=C(F)N=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)=CC=C1 OOSWMBBSRRRIQH-UHFFFAOYSA-N 0.000 description 1
- RDRKHWOTOSVRLY-UHFFFAOYSA-N CS(=O)(=O)NC1=CC(CC(=O)NC2=NN=C(CCCCC3=CN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)=CC=C1 Chemical compound CS(=O)(=O)NC1=CC(CC(=O)NC2=NN=C(CCCCC3=CN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)=CC=C1 RDRKHWOTOSVRLY-UHFFFAOYSA-N 0.000 description 1
- QWRSMGSETITNLD-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=C(CC(=O)NC2=NN=C(CCCCC3=CN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)C=C1 Chemical compound CS(=O)(=O)NC1=CC=C(CC(=O)NC2=NN=C(CCCCC3=CN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)S2)C=C1 QWRSMGSETITNLD-UHFFFAOYSA-N 0.000 description 1
- HVUJMANOMXOZGZ-UHFFFAOYSA-N C[Si](C)(C)C#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 Chemical compound C[Si](C)(C)C#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 HVUJMANOMXOZGZ-UHFFFAOYSA-N 0.000 description 1
- KSFINKNHAUQFRT-UHFFFAOYSA-N Cc([s]1)nnc1I Chemical compound Cc([s]1)nnc1I KSFINKNHAUQFRT-UHFFFAOYSA-N 0.000 description 1
- GVSNQMFKEPBIOY-UHFFFAOYSA-N Cc1c[nH]nn1 Chemical compound Cc1c[nH]nn1 GVSNQMFKEPBIOY-UHFFFAOYSA-N 0.000 description 1
- OLTGJRKGRLWVGC-UHFFFAOYSA-N Cc1ccc(CCc2ccc(CCc3cnc(C)cc3)nc2C)nc1F Chemical compound Cc1ccc(CCc2ccc(CCc3cnc(C)cc3)nc2C)nc1F OLTGJRKGRLWVGC-UHFFFAOYSA-N 0.000 description 1
- WZMOEPZZTTWDIA-UHFFFAOYSA-N Cc1ccncc1F Chemical compound Cc1ccncc1F WZMOEPZZTTWDIA-UHFFFAOYSA-N 0.000 description 1
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N Cc1cnc(C)[nH]1 Chemical compound Cc1cnc(C)[nH]1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 1
- MMDPOMLWHNQLOV-UHFFFAOYSA-N Cc1cnc(CCc(ccc(C)n2)c2F)cc1 Chemical compound Cc1cnc(CCc(ccc(C)n2)c2F)cc1 MMDPOMLWHNQLOV-UHFFFAOYSA-N 0.000 description 1
- ONIFNICATWBCHW-UHFFFAOYSA-N Cc1n[n](C)cn1 Chemical compound Cc1n[n](C)cn1 ONIFNICATWBCHW-UHFFFAOYSA-N 0.000 description 1
- XYYXDARQOHWBPO-UHFFFAOYSA-N Cc1nnc(C)[nH]1 Chemical compound Cc1nnc(C)[nH]1 XYYXDARQOHWBPO-UHFFFAOYSA-N 0.000 description 1
- ILEAPZYJOHTQMI-UHFFFAOYSA-N Cc1nnc(CCc(nc2)ccc2O)cc1 Chemical compound Cc1nnc(CCc(nc2)ccc2O)cc1 ILEAPZYJOHTQMI-UHFFFAOYSA-N 0.000 description 1
- KJJNVRVIXIYAHZ-UHFFFAOYSA-N Cl.O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC=C(C4CCNCC4)C=C3)S2)C=C1 Chemical compound Cl.O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC=C(C4CCNCC4)C=C3)S2)C=C1 KJJNVRVIXIYAHZ-UHFFFAOYSA-N 0.000 description 1
- FPKAXXTYCQPZMM-UHFFFAOYSA-N N#CC1=CC=CC(CC(=O)NC2=NN=C(CCCCC3=CC=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)N=C3)S2)=C1 Chemical compound N#CC1=CC=CC(CC(=O)NC2=NN=C(CCCCC3=CC=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)N=C3)S2)=C1 FPKAXXTYCQPZMM-UHFFFAOYSA-N 0.000 description 1
- GXUJRRLFJWQICN-OQFOIZHKSA-N N#CC1CC(=CC2=CC=C(N)N=C2)C1 Chemical compound N#CC1CC(=CC2=CC=C(N)N=C2)C1 GXUJRRLFJWQICN-OQFOIZHKSA-N 0.000 description 1
- DIJOEZXXDXMGJK-UUASQNMZSA-N N#CC1CC(=CC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)C1 Chemical compound N#CC1CC(=CC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)C1 DIJOEZXXDXMGJK-UUASQNMZSA-N 0.000 description 1
- OAMNTCYMDIIMTL-UUASQNMZSA-N N#CC1CC(=CC2=CC=C(NC(=O)CC3=CC=CN=C3)N=C2)C1 Chemical compound N#CC1CC(=CC2=CC=C(NC(=O)CC3=CC=CN=C3)N=C2)C1 OAMNTCYMDIIMTL-UUASQNMZSA-N 0.000 description 1
- FUXIOMKXDDIEKW-UHFFFAOYSA-N N#CC1CC(CC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)C1 Chemical compound N#CC1CC(CC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)C1 FUXIOMKXDDIEKW-UHFFFAOYSA-N 0.000 description 1
- JBVRUSZYOVWVKD-UHFFFAOYSA-N N#CC1CC(CC2=CC=C(NC(=O)CC3=CC=CN=C3)N=C2)C1 Chemical compound N#CC1CC(CC2=CC=C(NC(=O)CC3=CC=CN=C3)N=C2)C1 JBVRUSZYOVWVKD-UHFFFAOYSA-N 0.000 description 1
- IKVRJGXXYCLDLM-UHFFFAOYSA-N N#CCC1CCC(CC#N)CC1 Chemical compound N#CCC1CCC(CC#N)CC1 IKVRJGXXYCLDLM-UHFFFAOYSA-N 0.000 description 1
- ZTANLAODLCFZPJ-UHFFFAOYSA-N N#CCC1CCC(CC2=NN=C(N)S2)CC1 Chemical compound N#CCC1CCC(CC2=NN=C(N)S2)CC1 ZTANLAODLCFZPJ-UHFFFAOYSA-N 0.000 description 1
- BFCKSBZNDGVJKG-UHFFFAOYSA-N N#CCC1CCC(CC2=NN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)S2)CC1 Chemical compound N#CCC1CCC(CC2=NN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)S2)CC1 BFCKSBZNDGVJKG-UHFFFAOYSA-N 0.000 description 1
- DYFFXOCQZGLHHQ-UHFFFAOYSA-N N#CCCC#CC1=C(F)N=C(NC(=O)CC2=NC=CC=C2)C=C1 Chemical compound N#CCCC#CC1=C(F)N=C(NC(=O)CC2=NC=CC=C2)C=C1 DYFFXOCQZGLHHQ-UHFFFAOYSA-N 0.000 description 1
- NUGWSGZKCTYAQU-UHFFFAOYSA-N N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C(F)=C1 Chemical compound N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C(F)=C1 NUGWSGZKCTYAQU-UHFFFAOYSA-N 0.000 description 1
- AKEFOMHUFOJYLZ-UHFFFAOYSA-N N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1F Chemical compound N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1F AKEFOMHUFOJYLZ-UHFFFAOYSA-N 0.000 description 1
- ANQPBDHUMLJNMP-UHFFFAOYSA-N N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CC=N2)N=C1 Chemical compound N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CC=N2)N=C1 ANQPBDHUMLJNMP-UHFFFAOYSA-N 0.000 description 1
- UHEASRPLDPUIBS-UHFFFAOYSA-N N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CN=C2)N=C1 Chemical compound N#CCCC#CC1=CC=C(NC(=O)CC2=CC=CN=C2)N=C1 UHEASRPLDPUIBS-UHFFFAOYSA-N 0.000 description 1
- CTCRCDMETPNEQW-UHFFFAOYSA-N N#CCCC#CC1=CC=C(NC(=O)CC2=CC=NC=C2)N=C1 Chemical compound N#CCCC#CC1=CC=C(NC(=O)CC2=CC=NC=C2)N=C1 CTCRCDMETPNEQW-UHFFFAOYSA-N 0.000 description 1
- WHJNDZNIIUYOOS-UHFFFAOYSA-N N#CCCC#CC1=CN=C(N)C=C1 Chemical compound N#CCCC#CC1=CN=C(N)C=C1 WHJNDZNIIUYOOS-UHFFFAOYSA-N 0.000 description 1
- XOOLLKIQRFIQLL-UHFFFAOYSA-N N#CCCC#CC1=CN=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C=C1 Chemical compound N#CCCC#CC1=CN=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C=C1 XOOLLKIQRFIQLL-UHFFFAOYSA-N 0.000 description 1
- XHLXCLHRDNKLFW-UHFFFAOYSA-N N#CCCC#CC1=CN=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 Chemical compound N#CCCC#CC1=CN=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 XHLXCLHRDNKLFW-UHFFFAOYSA-N 0.000 description 1
- LNWXUJICJMCRMH-UHFFFAOYSA-N N#CCCC#CC1=CN=C(NC(=O)CC2=CC=CC=C2Cl)C=C1 Chemical compound N#CCCC#CC1=CN=C(NC(=O)CC2=CC=CC=C2Cl)C=C1 LNWXUJICJMCRMH-UHFFFAOYSA-N 0.000 description 1
- GINUXZQGSGEYAG-UHFFFAOYSA-N N#CCCC#CC1=NC=C(N)N=C1 Chemical compound N#CCCC#CC1=NC=C(N)N=C1 GINUXZQGSGEYAG-UHFFFAOYSA-N 0.000 description 1
- XFOYNMPTTKGIQF-UHFFFAOYSA-N N#CCCC#CC1=NC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C=C1 Chemical compound N#CCCC#CC1=NC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C=C1 XFOYNMPTTKGIQF-UHFFFAOYSA-N 0.000 description 1
- PIIIBJPXEMCOGF-UHFFFAOYSA-N N#CCCCCC1=C(F)N=C(NC(=O)CC2=NC=CC=C2)C=C1 Chemical compound N#CCCCCC1=C(F)N=C(NC(=O)CC2=NC=CC=C2)C=C1 PIIIBJPXEMCOGF-UHFFFAOYSA-N 0.000 description 1
- CMYTUDYCYKKNFZ-UHFFFAOYSA-N N#CCCCCC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C(F)=C1 Chemical compound N#CCCCCC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)C(F)=C1 CMYTUDYCYKKNFZ-UHFFFAOYSA-N 0.000 description 1
- JEWBNHOYOUJJDO-UHFFFAOYSA-N N#CCCCCC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1F Chemical compound N#CCCCCC1=CC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1F JEWBNHOYOUJJDO-UHFFFAOYSA-N 0.000 description 1
- UIBNVCUIRXRTDZ-UHFFFAOYSA-N N#CCCCCC1=CC=C(NC(=O)CC2=CC=CC=N2)N=C1 Chemical compound N#CCCCCC1=CC=C(NC(=O)CC2=CC=CC=N2)N=C1 UIBNVCUIRXRTDZ-UHFFFAOYSA-N 0.000 description 1
- BKMWHDCHYLGZCR-UHFFFAOYSA-N N#CCCCCC1=CC=C(NC(=O)CC2=CC=CN=C2)N=C1 Chemical compound N#CCCCCC1=CC=C(NC(=O)CC2=CC=CN=C2)N=C1 BKMWHDCHYLGZCR-UHFFFAOYSA-N 0.000 description 1
- VOBRZMQBRVVFFV-UHFFFAOYSA-N N#CCCCCC1=CN=C(N)C=C1 Chemical compound N#CCCCCC1=CN=C(N)C=C1 VOBRZMQBRVVFFV-UHFFFAOYSA-N 0.000 description 1
- JGUWWXCERCBGCH-UHFFFAOYSA-N N#CCCCCC1=CN=C(NC(=O)CC2=CC=CC=C2Cl)C=C1 Chemical compound N#CCCCCC1=CN=C(NC(=O)CC2=CC=CC=C2Cl)C=C1 JGUWWXCERCBGCH-UHFFFAOYSA-N 0.000 description 1
- JVSJYIFIBPJMRW-UHFFFAOYSA-N N#CCCCCC1=CN=C(NC(=O)CC2=CC=NC=C2)N=C1 Chemical compound N#CCCCCC1=CN=C(NC(=O)CC2=CC=NC=C2)N=C1 JVSJYIFIBPJMRW-UHFFFAOYSA-N 0.000 description 1
- XDYRPOLDUUVEHR-UHFFFAOYSA-N N#CCCCCC1=NC=C(N)N=C1 Chemical compound N#CCCCCC1=NC=C(N)N=C1 XDYRPOLDUUVEHR-UHFFFAOYSA-N 0.000 description 1
- DPCCCMHYBFSNBH-UHFFFAOYSA-N N#CCCCCC1=NC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 Chemical compound N#CCCCCC1=NC=C(NC(=O)CC2=CC=CC(OC(F)(F)F)=C2)N=C1 DPCCCMHYBFSNBH-UHFFFAOYSA-N 0.000 description 1
- NFLJOXQKSNBGQU-UHFFFAOYSA-N NC1=CN=C(Cl)C=C1.O=C(CC1=C(Cl)C=CC=C1)NC1=CN=C(Cl)C=C1.O=C(O)CC1=C(Cl)C=CC=C1.O=C(O)CC1=C(Cl)C=CC=C1 Chemical compound NC1=CN=C(Cl)C=C1.O=C(CC1=C(Cl)C=CC=C1)NC1=CN=C(Cl)C=C1.O=C(O)CC1=C(Cl)C=CC=C1.O=C(O)CC1=C(Cl)C=CC=C1 NFLJOXQKSNBGQU-UHFFFAOYSA-N 0.000 description 1
- DQQIOMIEIRYIIM-UHFFFAOYSA-N NC1=NN=C(C2CC(CC3=CC=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)N=C3)C2)S1 Chemical compound NC1=NN=C(C2CC(CC3=CC=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)N=C3)C2)S1 DQQIOMIEIRYIIM-UHFFFAOYSA-N 0.000 description 1
- GYYSYOUYZHWQNN-UHFFFAOYSA-N NC1=NN=C(C2CC(CC3=NN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)C2)S1 Chemical compound NC1=NN=C(C2CC(CC3=NN=C(NC(=O)CC4=CC=CC(OC(F)(F)F)=C4)C=C3)C2)S1 GYYSYOUYZHWQNN-UHFFFAOYSA-N 0.000 description 1
- DVTLFXQQUQWTOW-UHFFFAOYSA-N NC1=NN=C(C2CCC(C3=NN=C(N)S3)CC2)S1 Chemical compound NC1=NN=C(C2CCC(C3=NN=C(N)S3)CC2)S1 DVTLFXQQUQWTOW-UHFFFAOYSA-N 0.000 description 1
- CGKAFCDBMGXTKD-UHFFFAOYSA-N NC1=NN=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)C=C1 Chemical compound NC1=NN=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)C=C1 CGKAFCDBMGXTKD-UHFFFAOYSA-N 0.000 description 1
- CDAMECTYENXBNW-UHFFFAOYSA-N NC1=NN=C(CC2CCC(CC3=NN=C(N)S3)CC2)S1 Chemical compound NC1=NN=C(CC2CCC(CC3=NN=C(N)S3)CC2)S1 CDAMECTYENXBNW-UHFFFAOYSA-N 0.000 description 1
- GRUMNKFVNAYFKA-UHFFFAOYSA-N NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)S3)CC2)S1 Chemical compound NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)S3)CC2)S1 GRUMNKFVNAYFKA-UHFFFAOYSA-N 0.000 description 1
- LYFOHVNXDPDJIK-UHFFFAOYSA-N NC1=NN=C(CCC#CC2=CN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C=C2)S1 Chemical compound NC1=NN=C(CCC#CC2=CN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C=C2)S1 LYFOHVNXDPDJIK-UHFFFAOYSA-N 0.000 description 1
- WITUHSKKEXDFGF-UHFFFAOYSA-N NC1=NN=C(CCC#CC2=CN=C(NC(=O)CC3=CC=CC=C3Cl)C=C2)S1 Chemical compound NC1=NN=C(CCC#CC2=CN=C(NC(=O)CC3=CC=CC=C3Cl)C=C2)S1 WITUHSKKEXDFGF-UHFFFAOYSA-N 0.000 description 1
- RJGSUXDAHQWEQO-UHFFFAOYSA-N NC1=NN=C(CCC#CC2=NC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C=C2)S1 Chemical compound NC1=NN=C(CCC#CC2=NC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C=C2)S1 RJGSUXDAHQWEQO-UHFFFAOYSA-N 0.000 description 1
- SGWMPAHXZMHPRJ-UHFFFAOYSA-N NC1=NN=C(CCCCC2=C(F)N=C(NC(=O)CC3=NC=CC=C3)C=C2)S1 Chemical compound NC1=NN=C(CCCCC2=C(F)N=C(NC(=O)CC3=NC=CC=C3)C=C2)S1 SGWMPAHXZMHPRJ-UHFFFAOYSA-N 0.000 description 1
- CUZJECKFILPHSK-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C(F)=C2)S1 Chemical compound NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C(F)=C2)S1 CUZJECKFILPHSK-UHFFFAOYSA-N 0.000 description 1
- QENSYURRMNNVMI-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C=N2)S1 Chemical compound NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)C=N2)S1 QENSYURRMNNVMI-UHFFFAOYSA-N 0.000 description 1
- SDVJFUMWOJUHSD-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 Chemical compound NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 SDVJFUMWOJUHSD-UHFFFAOYSA-N 0.000 description 1
- PBMOSKBMEKAOMD-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2F)S1 Chemical compound NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2F)S1 PBMOSKBMEKAOMD-UHFFFAOYSA-N 0.000 description 1
- FYOVWDJLMAQXOV-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC=N3)N=C2)S1 Chemical compound NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CC=N3)N=C2)S1 FYOVWDJLMAQXOV-UHFFFAOYSA-N 0.000 description 1
- AOXWEQIBGYPAIV-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CN=C3)N=C2)S1 Chemical compound NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=CN=C3)N=C2)S1 AOXWEQIBGYPAIV-UHFFFAOYSA-N 0.000 description 1
- RORWFKMUSARLFE-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=NC=C3)N=C2)S1 Chemical compound NC1=NN=C(CCCCC2=CC=C(NC(=O)CC3=CC=NC=C3)N=C2)S1 RORWFKMUSARLFE-UHFFFAOYSA-N 0.000 description 1
- GJZKKKUKVOUSAW-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 Chemical compound NC1=NN=C(CCCCC2=CN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 GJZKKKUKVOUSAW-UHFFFAOYSA-N 0.000 description 1
- XGNWVTYJUAXDIH-UHFFFAOYSA-N NC1=NN=C(CCCCC2=CN=C(NC(=O)CC3=CC=CC=C3Cl)C=C2)S1 Chemical compound NC1=NN=C(CCCCC2=CN=C(NC(=O)CC3=CC=CC=C3Cl)C=C2)S1 XGNWVTYJUAXDIH-UHFFFAOYSA-N 0.000 description 1
- QTMSKVHAVOMGIB-UHFFFAOYSA-N NC1=NN=C(CCCCC2=NC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 Chemical compound NC1=NN=C(CCCCC2=NC=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)N=C2)S1 QTMSKVHAVOMGIB-UHFFFAOYSA-N 0.000 description 1
- UYXFJPDAUMCTDJ-UHFFFAOYSA-N O=C(CC1=CC(OC(F)(F)F)=CC=C1)NC1=CC=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CC=N4)S3)C2)C=N1 Chemical compound O=C(CC1=CC(OC(F)(F)F)=CC=C1)NC1=CC=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CC=N4)S3)C2)C=N1 UYXFJPDAUMCTDJ-UHFFFAOYSA-N 0.000 description 1
- AHCIEAVSKZMFER-UHFFFAOYSA-N O=C(CC1=CC(OC(F)(F)F)=CC=C1)NC1=CC=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CN=C4)S3)C2)C=N1 Chemical compound O=C(CC1=CC(OC(F)(F)F)=CC=C1)NC1=CC=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CN=C4)S3)C2)C=N1 AHCIEAVSKZMFER-UHFFFAOYSA-N 0.000 description 1
- JUYHWENLWUHXEE-UHFFFAOYSA-N O=C(CC1=CC(OC(F)(F)F)=CC=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CC=CC=N4)S3)CC2)S1 Chemical compound O=C(CC1=CC(OC(F)(F)F)=CC=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CC=CC=N4)S3)CC2)S1 JUYHWENLWUHXEE-UHFFFAOYSA-N 0.000 description 1
- AJDWWGHNEFYCGD-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)CC1=NN=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CC=N4)S3)C2)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)CC1=NN=C(CC2CC(C3=NN=C(NC(=O)CC4=CC=CC=N4)S3)C2)C=C1 AJDWWGHNEFYCGD-UHFFFAOYSA-N 0.000 description 1
- UFTRYLACPWUFEM-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(Br)C(F)=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(Br)C(F)=N1 UFTRYLACPWUFEM-UHFFFAOYSA-N 0.000 description 1
- DGUYLWROYKTNNO-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(Br)C=C1F Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(Br)C=C1F DGUYLWROYKTNNO-UHFFFAOYSA-N 0.000 description 1
- JXJCGVVOLMIIGT-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(C#CC#CC2=CN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)C=C2)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(C#CC#CC2=CN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)C=C2)C=N1 JXJCGVVOLMIIGT-UHFFFAOYSA-N 0.000 description 1
- MQKSLIKUGSCFMY-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=CN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)C=C2)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=CN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)C=C2)C=N1 MQKSLIKUGSCFMY-UHFFFAOYSA-N 0.000 description 1
- HPUNMVVMMDAQPM-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC(OC(F)(F)F)=CC=C3)S2)C=N1 HPUNMVVMMDAQPM-UHFFFAOYSA-N 0.000 description 1
- RATTYKJQHBVWMU-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=C1F Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=C1F RATTYKJQHBVWMU-UHFFFAOYSA-N 0.000 description 1
- MWQHDHACYVMQLI-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=N1 MWQHDHACYVMQLI-UHFFFAOYSA-N 0.000 description 1
- BQYZPWSJNONGBG-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)N=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)N=C1 BQYZPWSJNONGBG-UHFFFAOYSA-N 0.000 description 1
- SFRACOFTBJWIAY-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CN=C3)S2)C=C1F Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CN=C3)S2)C=C1F SFRACOFTBJWIAY-UHFFFAOYSA-N 0.000 description 1
- FYNSBHJFJQFNSO-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CN=C3)S2)N=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CN=C3)S2)N=C1 FYNSBHJFJQFNSO-UHFFFAOYSA-N 0.000 description 1
- VNJNRPUGBAXHSZ-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=C3)S2)C(F)=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=C3)S2)C(F)=N1 VNJNRPUGBAXHSZ-UHFFFAOYSA-N 0.000 description 1
- AKZBDFNFHJJFNJ-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=N3)S2)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=N3)S2)C=N1 AKZBDFNFHJJFNJ-UHFFFAOYSA-N 0.000 description 1
- QXGPKRONKYEFAU-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CN3C=CC=N3)S2)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CN3C=CC=N3)S2)C=N1 QXGPKRONKYEFAU-UHFFFAOYSA-N 0.000 description 1
- MQQRYYDZIOGOJB-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CN=C(Br)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=CN=C(Br)C=C1 MQQRYYDZIOGOJB-UHFFFAOYSA-N 0.000 description 1
- OMHDYAHYIGXONI-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC(F)=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC(F)=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=C1 OMHDYAHYIGXONI-UHFFFAOYSA-N 0.000 description 1
- YTPVOFGJQPBUTN-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(Br)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(Br)C=C1 YTPVOFGJQPBUTN-UHFFFAOYSA-N 0.000 description 1
- VBXKVSIFGMYPFJ-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(Br)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(Br)C=N1 VBXKVSIFGMYPFJ-UHFFFAOYSA-N 0.000 description 1
- CXGFIYZASOAVEQ-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(C#CCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(C#CCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=C1 CXGFIYZASOAVEQ-UHFFFAOYSA-N 0.000 description 1
- QCHBNXWIHXNUHN-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=N1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=N1 QCHBNXWIHXNUHN-UHFFFAOYSA-N 0.000 description 1
- MFKIVRBSMNYCRJ-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)N=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)N=C1 MFKIVRBSMNYCRJ-UHFFFAOYSA-N 0.000 description 1
- BFFNCCTZICNRSR-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CN3N=C(C(F)(F)F)C=C3C(F)(F)F)S2)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NC=C(CCCCC2=NN=C(NC(=O)CN3N=C(C(F)(F)F)C=C3C(F)(F)F)S2)C=C1 BFFNCCTZICNRSR-UHFFFAOYSA-N 0.000 description 1
- WEKCICRYLYLXQH-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CC(C(=O)O)C2)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CC(C(=O)O)C2)C=C1 WEKCICRYLYLXQH-UHFFFAOYSA-N 0.000 description 1
- GWLRLAVFGQJVRL-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)C=C1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CC(C(=O)OCC3=CC=CC=C3)C2)C=C1 GWLRLAVFGQJVRL-UHFFFAOYSA-N 0.000 description 1
- MOQQCAPZNORTMV-UHFFFAOYSA-N O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)S3)CC2)S1 Chemical compound O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CC(OC(F)(F)F)=CC=C4)S3)CC2)S1 MOQQCAPZNORTMV-UHFFFAOYSA-N 0.000 description 1
- HOZKSWTWQYZYDB-UHFFFAOYSA-N O=C(CC1=CC=CC=C1Cl)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=N1 Chemical compound O=C(CC1=CC=CC=C1Cl)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC=N3)S2)C=N1 HOZKSWTWQYZYDB-UHFFFAOYSA-N 0.000 description 1
- DQKXZECESZMTTD-UHFFFAOYSA-N O=C(CC1=CC=CC=C1Cl)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CN=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CC=C1Cl)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CN=C3)S2)C=N1 DQKXZECESZMTTD-UHFFFAOYSA-N 0.000 description 1
- RHQMYLFVYONMRK-UHFFFAOYSA-N O=C(CC1=CC=CC=C1Cl)NC1=NC=C(Br)C=C1 Chemical compound O=C(CC1=CC=CC=C1Cl)NC1=NC=C(Br)C=C1 RHQMYLFVYONMRK-UHFFFAOYSA-N 0.000 description 1
- HXAWCCAIWXKGLU-UHFFFAOYSA-N O=C(CC1=CC=CC=N1)NC1=CC=C(Br)C=N1 Chemical compound O=C(CC1=CC=CC=N1)NC1=CC=C(Br)C=N1 HXAWCCAIWXKGLU-UHFFFAOYSA-N 0.000 description 1
- LBEOYPGLAFDAKJ-UHFFFAOYSA-N O=C(CC1=CC=CC=N1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CC=N1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=N1 LBEOYPGLAFDAKJ-UHFFFAOYSA-N 0.000 description 1
- YBMQTIQAYIIENZ-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=CC=C(Br)C=N1 Chemical compound O=C(CC1=CC=CN=C1)NC1=CC=C(Br)C=N1 YBMQTIQAYIIENZ-UHFFFAOYSA-N 0.000 description 1
- NHWWIWDASPDSTJ-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=C(Cl)C=CC=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=C(Cl)C=CC=C3)S2)C=N1 NHWWIWDASPDSTJ-UHFFFAOYSA-N 0.000 description 1
- JTFJSVBNPFPOKY-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=C(F)C=CC=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=C(F)C=CC=C3)S2)C=N1 JTFJSVBNPFPOKY-UHFFFAOYSA-N 0.000 description 1
- CIBITYJLJVAMOZ-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC(Cl)=CC=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC(Cl)=CC=C3)S2)C=N1 CIBITYJLJVAMOZ-UHFFFAOYSA-N 0.000 description 1
- NTLARVBIEKJZFM-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC(F)=CC=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC(F)=CC=C3)S2)C=N1 NTLARVBIEKJZFM-UHFFFAOYSA-N 0.000 description 1
- WDZQLWXIWAOWDR-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=N1 Chemical compound O=C(CC1=CC=CN=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=N1 WDZQLWXIWAOWDR-UHFFFAOYSA-N 0.000 description 1
- NNUKBRBXZDOXKT-UHFFFAOYSA-N O=C(CC1=CC=CN=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CN=CC=C4)S3)CC2)S1 Chemical compound O=C(CC1=CC=CN=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=CN=CC=C4)S3)CC2)S1 NNUKBRBXZDOXKT-UHFFFAOYSA-N 0.000 description 1
- ASBDBZBSMRMQCA-UHFFFAOYSA-N O=C(CC1=CC=NC=C1)NC1=CC=C(Br)C=N1 Chemical compound O=C(CC1=CC=NC=C1)NC1=CC=C(Br)C=N1 ASBDBZBSMRMQCA-UHFFFAOYSA-N 0.000 description 1
- SZGJVPQZULIFOU-UHFFFAOYSA-N O=C(CC1=CC=NC=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=N1 Chemical compound O=C(CC1=CC=NC=C1)NC1=CC=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=N1 SZGJVPQZULIFOU-UHFFFAOYSA-N 0.000 description 1
- YXIAJDWGCRHQKK-UHFFFAOYSA-N O=C(CC1=NC=CC=C1)NC1=NC(F)=C(Br)C=C1 Chemical compound O=C(CC1=NC=CC=C1)NC1=NC(F)=C(Br)C=C1 YXIAJDWGCRHQKK-UHFFFAOYSA-N 0.000 description 1
- JDYGSMFEMNSRDP-UHFFFAOYSA-N O=C(CC1=NC=CC=C1)NC1=NC(F)=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=C1 Chemical compound O=C(CC1=NC=CC=C1)NC1=NC(F)=C(CCCCC2=NN=C(NC(=O)CC3=CC=CC(OC(F)(F)F)=C3)S2)C=C1 JDYGSMFEMNSRDP-UHFFFAOYSA-N 0.000 description 1
- CBVPHQDNJVBUAF-UHFFFAOYSA-N O=C(CC1=NC=CC=C1)NC1=NC(F)=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=C3)S2)C=C1 Chemical compound O=C(CC1=NC=CC=C1)NC1=NC(F)=C(CCCCC2=NN=C(NC(=O)CC3=CN=CC=C3)S2)C=C1 CBVPHQDNJVBUAF-UHFFFAOYSA-N 0.000 description 1
- VBIKDQUKQWLKTN-UHFFFAOYSA-N O=C(CC1=NC=CC=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)CC2)S1 Chemical compound O=C(CC1=NC=CC=C1)NC1=NN=C(CC2CCC(CC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)CC2)S1 VBIKDQUKQWLKTN-UHFFFAOYSA-N 0.000 description 1
- FWCABFRPKRKQID-UHFFFAOYSA-N O=C(OCC1=CC=CC=C1)C1CC(CBr)C1 Chemical compound O=C(OCC1=CC=CC=C1)C1CC(CBr)C1 FWCABFRPKRKQID-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders involving glutamine.
- Glutaminase (glutaminase I, L-glutaminase, glutamine aminohydrolase) is an amido-hydrolase enzyme that generates glutamate from glutamine. Glutaminase has been reported to have tissue-specific isoenzymes. Glutaminase has an important role in glial cells. Glutamine is the most abundant free amino acid in the human body; it is essential for the growth of normal and neoplastic cells and for the culture of many cell types. Glutamine is an important source of energy for neoplastic tissues, and products of its metabolism include, among others, glutamate (Glu) and glutathione (GSH), the two molecules that play a key role in tumor proliferation, invasiveness and resistance to therapy.
- Glu glutamate
- GSH glutathione
- Glutamine hydrolysis in normal and transforming mammalian tissues alike is carried out by different isoforms of glutaminases, of which the two major types are liver-type glutaminase (LGA) and kidney-type glutaminase (KGA) (see Neurochem Int., 2009 July-August; 55(1-3):71-5. doi: 10.1016/j.neuint.2009.01.008. Epub 2009 February).
- LGA liver-type glutaminase
- KGA kidney-type glutaminase
- Glutaminase is the first enzyme that converts glutamine to glutamate, which is in turn converted to alpha-ketoglutarate for further metabolism in the tricarboxylic acid cycle.
- GA isoforms in mammals are encoded by two genes, Gls and Gls2.
- Gls and Gls2 As each enzymatic form of GA has distinct kinetic and molecular characteristics, it has been speculated that the differential regulation of GA isoforms may reflect distinct functions or requirements in different tissues or cell states.
- GA encoded by the Gls gene (GLS) has been demonstrated to be regulated by oncogenes and to support tumor cell growth.
- GA encoded by the Gls2 gene (GLS2) reduces cellular sensitivity to reactive oxygen species associated apoptosis possibly through glutathione-dependent antioxidant defense, and therefore to behave more like a tumor suppressor.
- modulation of GA function may be a new therapeutic target for cancer treatment (see Matds et al., Curr. Mol. Med., 2013 May; 13(4), 514-534).
- Glutaminase a mitochondrial enzyme, plays a key role in the metabolism of glutamine in cancer cells, and its inhibition could significantly impact malignant transformation (see Katt et al., Mol. Cancer Ther., 11(6); 1269-78, 2012). Feeding off the breakdown of glutamine, cancer cells are able to grow and divide into a tumour. Glutaminase therefore makes a promising therapeutic target for the prevention of tumour progression. Inhibition of this enzyme could effectively starve the cancer cells of their energy source. See Medina et al., J. Nutr ., Sep. 1, 2001, Vol. 131, No. 9 2539S-2542S.
- glutaminase inhibitors namely 6-diazo-5-oxo-L-norleucine (DON) which was isolated originally from Streptomyces in a sample of Peruvian soil and was characterized in 1956 by Henry W Dion (see Dion et al., Antibiotics and Chemotherapy, 1954, 78, 3075-3077) and suggested as a cancer therapy and bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) disclosed by Elan Pharmaceuticals.
- DON 6-diazo-5-oxo-L-norleucine
- BPTES bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide
- Patent literature related to glutaminase inhibitors includes International Publication Nos. WO 99/09825, WO 00/59533, WO 03/022261, WO 04/108153, WO 07/128588, WO 10/033871, WO 10/111504, WO 11/076967, WO 11/143160, WO 12/006506, WO 12/034123, WO 13/044596, WO 13/078123, WO 14/078645, WO 14/089048, WO 14/043633, WO 14/079011, WO 14/079136, WO 14/079150, and WO 14/081925, U.S. Publication Nos.
- the present invention relates to compounds of formulas (I) to (III), methods for their preparation, pharmaceutical compositions containing them, and methods of treatment with them.
- the compounds of formula (I) to (III) and their pharmaceutically acceptable salts thereof are useful in the treatment, prevention and/or amelioration of diseases or disorders involving glutamine.
- the present invention relates to a compound of formula (I):
- L is -L 1 -L 2 -L 3 -;
- L 1 is absent or selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x —;
- L 2 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, or substituted or unsubstituted C 2-6 alkynyl;
- L 3 is absent or selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x —;
- a and B are selected from
- each of A and B are optionally substituted with one or more R 3 ;
- each of A and B are optionally substituted with one or more R 3 ;
- each occurrence of R 3 is, independently, halogen or substituted or unsubstituted C 1-3 alkyl, amino, nitro or substituted or unsubstituted C 1-3 alkoxy;
- P and Q are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, NR x —C( ⁇ O)—(CR x R y ) r —, —NH—C( ⁇ O)—C(R x R y )—, —(CR x R y ) r —C( ⁇ O)—NR x —, —(CR x R y )—C( ⁇ O)—NH—, —C( ⁇ O)NR x —(CR x R y ) r —, —C( ⁇ O)NH—C(R x R y )—, —(CR x R y ) r —NR x —C( ⁇ O)—, —(CR x R y )—NH—C( ⁇ O)—,
- R 1 and R 2 are independently selected from hydrogen, hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —C( ⁇ O)OR z , —C( ⁇ O)R
- each occurrence of R x , R y and R z is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, or substituted or unsubstituted amino, or any two of R x and R y when bound to a common atom may be joined to form (i)
- each occurrence of q is independently 0, 1 or 2 and
- each occurrence of r is independently 0, 1 or 2.
- formulas are to be read in the direction they are shown. For example, (a) if P is —CH 2 —C( ⁇ O)—NH— in formula (I) (i.e., —R 1 —P-A-L-B-Q-R 2 ) than the compound would have the formula R 1 —CH 2 —C(O)—NH-A-L-B-Q-R 2 or (b) if P is —CH 2 —C( ⁇ O)—NH— and Q is —NH—C( ⁇ O)—CH 2 — in formula (I) (i.e., R 1 —P-A-L-B-Q-R 2 ) than the compound would have the formula R 1 —CH 2 —C(O)—NH-A-L-B—NH—C( ⁇ O)—CH 2 —R 2 .
- a and B are selected from
- each occurrence of R 3 is independently, halogen, substituted or unsubstituted C 1-3 alkyl, amino, nitro or substituted or unsubstituted C 1-3 alkoxy;
- A is selected from
- R 3 is hydrogen, halogen or substituted or unsubstituted C 1-3 alkyl (e.g., methyl).
- A is selected from
- R 3 is hydrogen, halogen or substituted or unsubstituted C 1-3 alkyl (e.g., methyl);
- A is selected from
- A is selected from
- A is selected from
- L is -L 1 -L 2 -L 3 -;
- L 1 is absent or independently selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x —;
- L 2 is substituted or unsubstituted C 3-10 cycloalkyl
- L 3 is absent or independently selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x —;
- a and B are selected from
- each of A and B are optionally substituted with one or more R 3 ;
- each of A and B are optionally substituted with one or more R 3 ;
- both A and B are independently selected from
- each of A and B are optionally substituted with one or more R 3 ;
- each occurrence of R 3 is, independently, hydrogen, halogen, substituted or unsubstituted C 1-3 alkyl, amino, substituted or unsubstituted C 1-6 alkoxy, or substituted or unsubstituted C 1-6 alkylamino;
- P and Q are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, NR x —C( ⁇ O)—(CR x R y ) r —, —NH—C( ⁇ O)—C(R x R y )—, —(CR x R y ) r —C( ⁇ O)—NR x —, —(CR x R y )—C( ⁇ O)—NH—, —C( ⁇ O)NR x —(CR x R y ) r —, —C( ⁇ O)NH—C(R x R y )—, —(CR x R y ) r —NR x —C( ⁇ O)—, —(CR x R y )—NH—C( ⁇ O)—,
- R 1 and R 2 are independently selected from hydrogen, hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —C( ⁇ O)OR z , —C( ⁇ O)R
- each occurrence of R x , R y and R z is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, or substituted or unsubstituted amino, or any two of R x and R y when bound to a common atom may be joined to form (i)
- each occurrence of q is independently 0, 1 or 2 and
- each occurrence of r is independently 0, 1 or 2.
- formulas are to be read in the direction they are shown. For example, (a) if P is —CH 2 —C( ⁇ O)—NH— in formula (II) (i.e., —R 1 —P-A-L-B-Q-R 2 ) than the compound would have the formula R 1 —CH 2 —C(O)—NH-A-L-B-Q-R 2 or (b) if P is —CH 2 —C( ⁇ O)—NH— and Q is —NH—C( ⁇ O)—CH 2 — in formula (II) (i.e., R 1 —P-A-L-B-Q-R 2 ) than the compound would have the formula R 1 —CH 2 —C(O)—NH-A-L-B—NH—C( ⁇ O)—CH 2 —R 2 .
- A is selected from
- A is selected from
- the present invention also relates to a compound of formula (III):
- L is -L 1 -L 2 -L 3 -;
- L 1 is absent or independently selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x —;
- L 2 is substituted or unsubstituted C 4-10 cycloalkyl
- L 3 is absent or independently selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x —;
- a and B are selected from
- each of A and B are optionally substituted with one or more R 3 ;
- each of A and B are optionally substituted with one or more R 3 ;
- each occurrence of R 3 is, independently, hydrogen, halogen, substituted or unsubstituted C 1-3 alkyl, amino, nitro or substituted or unsubstituted C 1-3 alkoxy;
- P and Q are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, NR x —C( ⁇ O)—(CR x R y ) r —, —NH—C( ⁇ O)—C(R x R y )—, —(CR x R y ) r —C( ⁇ O)—NR x —, —(CR x R y )—C( ⁇ O)—NH—, —C( ⁇ O)NR x —(CR x R y ) r —, —C( ⁇ O)NH—C(R x R y )—, —(CR x R y ) r —NR x —C( ⁇ O)—, —(CR x R y )—NH—C( ⁇ O)—,
- R 1 and R 2 are independently selected from hydrogen, hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —C( ⁇ O)OR z , —C( ⁇ O)R
- each occurrence of R x , R y and R z is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, or substituted or unsubstituted amino, or any two of R x and R y when bound to a common atom may be joined to form (i)
- each occurrence of q is independently 0, 1 or 2;
- each occurrence of r is independently 0, 1 or 2.
- formulas are to be read in the direction they are shown. For example, (a) if P is —CH 2 —C( ⁇ O)—NH— in formula (III) (i.e., R 1 —P-A-L-B-Q-R 2 ) than the compound would have the formula R 1 —CH 2 —C(O)—NH-A-L-B-Q-R 2 or (b) if P is —CH 2 —C( ⁇ O)—NH— and Q is —NH—C( ⁇ O)—CH 2 — in formula (III) (i.e., —R 1 —P-A-L-B-Q-R 2 ) than the compound would have the formula R 1 —CH 2 —C(O)—NH-A-L-B—NH—C( ⁇ O)—CH 2 —R 2 .
- each of A and B is optionally substituted with one or more R 3 ; or (ii) A is selected from
- each of A and B are optionally substituted with one or more R 3 ; and each occurrence of R 3 is, independently, hydrogen, halogen, substituted or unsubstituted C 1-3 alkyl, amino, nitro or substituted or unsubstituted C 1-3 alkoxy.
- each of A and B is optionally substituted with one or more R 3 ; or (ii) A is selected from
- each of A and B is optionally substituted with one or more R 3 ; each occurrence of R 3 is independently hydrogen, halogen, substituted or unsubstituted C 1-3 alkyl, amino, nitro or substituted or unsubstituted C 1-3 alkoxy. Further preferred is a compound having the formula (III), wherein
- each of A and B is optionally substituted with one or more R 3 ;
- each of P and Q are independently selected from —NR x C( ⁇ O)—(CR x R y ) r —, —(CR x R y ) r —C( ⁇ O)—NR x —, —C( ⁇ O)NR x —(CR x R y ) r —, —(CR x R y ) r —NR x —C( ⁇ O)—, —NH—C( ⁇ O)—C(R x R y )—, —(CR x R y )—C( ⁇ O)—NH—, —NR x C( ⁇ O)—, —NR x C( ⁇ S)—, —NR x S( ⁇ O) q —, —C( ⁇ O)NR z —, —C( ⁇ S)NR z —, or —NR x x
- each of P and Q are independently selected from —NR x C( ⁇ O)—(CR x R y )—, —(CR x R y )—C( ⁇ O)—NR x —, —NR x C( ⁇ O)— or —NR x —, wherein R x and R y are independently selected from hydrogen, substituted or unsubstituted C 1-3 alkyl, halogen, hydroxy and substituted or unsubstituted C 1-3 alkoxy.
- each of P and Q are independently —NH—C( ⁇ O)—(CR x R y )—, —(CR x R y )—C( ⁇ O)—NH—, —NH—C( ⁇ O)— or —NH—, wherein R x and R y are hydrogen.
- each of P and Q are independently —NH—C( ⁇ O)—(CH 2 )—, —(CH 2 )—C( ⁇ O)—NH—, —NH—C( ⁇ O)— or —NH—.
- Yet another embodiment is a compound having the formula (IB), (IC), (ID) or (IE):
- each occurrence of R 3 is independently hydrogen, halogen, substituted or unsubstituted C 1-3 alkyl, amino, nitro or C 1-3 alkoxy;
- L 1 is absent, substituted or unsubstituted C 1-6 alkyl or NR x , wherein R x is hydrogen or substituted or unsubstituted C 1-3 alkyl;
- L 2 is substituted or unsubstituted C 1-4 alkyl or substituted or unsubstituted C 2-4 alkynyl;
- L 3 is absent, substituted or unsubstituted C 1-6 alkyl or NR x , wherein R x is hydrogen or substituted or unsubstituted C 1-3 alkyl.
- L 2 is substituted or unsubstituted C 1-4 alkyl
- Yet another embodiment is a compound having the formula (IIIA) or (IIIB):
- each occurrence of R a , R b , R c , R d , R e , R f , R g and R h is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl; or any two of R a , R b , R c , R d , R e , R f , R g and R h (such as two groups bound to a common atom or adjacent atoms or any two groups which when joined form a chemically stable structure) may be joined to form (i
- each of s, t, u and v is 0, 1 or 2 with the proviso that the sum of s, t, u and v is not 0 (i.e., s+t+u+v is at least 1).
- each occurrence of R a , R b , R c , R d , R e , R f , R g and R h is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl, or any two of R a , R b , R c , R d , R e , R f , R g and R h (such as two groups bound to a common atom or adjacent atoms or any two groups which when joined form a chemically stable structure) may be joined to form (i
- each of s, t, u and v is 0, 1 or 2 with the proviso that the sum of s, t, u and v is not 0 or 1 (i.e., the sum of s, t, u, and v is at least 2).
- each occurrence of R a , R b , R c , R d , R e , R f , R g and R h is independently selected from hydrogen, hydroxy, C 1-3 alkyl or any two of R a , R b , R c , R d , R e , R f , R g and R h , when bound to a common atom, may be joined to form oxo ( ⁇ O) or substituted or unsubstituted cycloalkyl group.
- each of R a , R b , R c , R d , R e , R f , R g and R h is hydrogen and the sum of s, t, u and v is 1-4, such as 1, 2, 3 or 4.
- each of R a , R b , R c , R d , R e , R f , R g and R h is hydrogen and the sum of s, t, u and v is 2 to 4 (i.e., 2, 3 or 4).
- each of R a , R b , R c , R d , R e , R f , R g and R h is hydrogen and s is 0, t is 1 and the sum of u and v is 1, 2 or 3.
- L 1 is absent, substituted or unsubstituted C 1-6 alkyl or NR x , wherein R x is hydrogen or substituted or unsubstituted C 1-3 alkyl;
- L 2 is substituted or unsubstituted C 4-8 cycloalkyl
- L 3 is absent, substituted or unsubstituted C 1-6 alkyl or NR x , wherein R x is hydrogen or substituted or unsubstituted C 1-3 alkyl.
- L 1 is absent or substituted or unsubstituted C 1-6 alkyl
- L 2 is substituted or unsubstituted C 4-8 cycloalkyl
- L 3 is absent or substituted or unsubstituted C 1-6 alkyl.
- L 1 is absent and L 3 is —CH 2 —;
- L 1 is —CH 2 — and L 3 is absent.
- R 3 is independently selected from halogen and substituted or unsubstituted C 1-3 alkyl.
- R 3 is independently selected from hydrogen, halogen and substituted or unsubstituted C 1-3 alkyl.
- R 1 and R 2 are independently selected from halogen, substituted or unsubstituted alkyl, —NR z R z , substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl.
- R 1 and R 2 are independently selected from —NR z R z , substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
- each of R 1 and R 2 is independently selected from substituted and unsubstituted aryl.
- each of R 1 and R 2 is independently selected from substituted and unsubstituted heteroaryl.
- R 1 is substituted or unsubstituted aryl and R 2 is substituted or unsubstituted heteroaryl;
- R 1 is substituted or unsubstituted heteroaryl and R 2 is substituted or unsubstituted aryl;
- both R 1 and R 2 are independently substituted or unsubstituted aryl;
- R 1 and R 2 are independently substituted or unsubstituted heteroaryl
- Representative compounds of the present invention include those listed below (see also Tables 1 and 2) and pharmaceutically acceptable salts thereof. The present invention should not be construed to be limited to these compounds.
- Yet another embodiment of the present invention is a method for inhibiting glutaminase in a patient by administering to the patient an effective amount of at least one compound of the present invention (for example, a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (II), (III), (IIIA), or (IIIB) as defined above).
- a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (II), (III), (IIIA), or (IIIB) as defined above for example, a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (II), (III), (IIIA), or (IIIB) as defined above.
- Yet another embodiment of the present invention is a method for treating an inflammatory, autoimmune or proliferative disease (e.g., via inhibition of glutaminase) by administering to a patient in need of such treatment an effective amount of at least one compound of the present invention.
- the compound of the present invention inhibits glutaminase (i.e., an effective amount of the compound is administered to inhibit glutaminase).
- Yet another embodiment of the present invention is a method for treating a inflammatory, autoimmune or proliferative disease (e.g., via inhibition of glutaminase) by administering to a patient in need of such treatment an effective amount of at least one compound of the present invention, in combination (simultaneously or sequentially) with at least one other anti-inflammatory, immunomodulator or anti-cancer agent.
- the compound of the present invention inhibits glutaminase.
- the compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (II), (III), (IIIA), and (IIIB) and pharmaceutically acceptable esters or salts thereof can be administered for the treatment, prevention and/or amelioration of diseases or disorders associated with glutamine, in particular the amelioration of diseases or disorders mediated by glutamine, including, but not limited to, inflammatory diseases or disorders, autoimmune diseases or disorders, and cancer and other proliferative diseases or disorders.
- the compounds of the present invention are useful in the treatment of a variety of cancers, including, but not limited to:
- the glutaminase inhibitors of the present invention may act as reversible cytostatic agents and therefore may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritic disease (e.g., arthritis), psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
- any disease process e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritic disease (e.g., arthritis), psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertroph
- the compounds of the present invention as modulators of apoptosis are useful in the treatment of cancer (including but not limited to those types mentioned herein above), viral infections (including but not limited to herpevirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, athe
- the compounds of present invention can modulate the level of cellular RNA and DNA synthesis. These agents are therefore useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus).
- viral infections including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus.
- the compounds of the present invention are useful in the chemoprevention of cancer.
- Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
- the compounds described herein are also useful in inhibiting tumor angiogenesis and metastasis.
- One embodiment of the invention is a method of inhibiting tumor angiogenesis or metastasis in a patient in need thereof by administering an effective amount of one or more compounds of the present invention.
- Another embodiment of the present invention is a method of treating an immune system-related disease (e.g., an autoimmune disease), a disease or disorder involving inflammation (e.g., asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, neuroinflammatory diseases, multiple sclerosis, uveitis and disorders of the immune system), cancer or other proliferative disease, a hepatic disease or disorder, or a renal disease or disorder.
- the method includes administering an effective amount of one or more compounds of the present invention.
- immune disorders include, but are not limited to, psoriasis, rheumatoid arthritis, vasculitis, inflammatory bowel disease, dermatitis, osteoarthritis, asthma, inflammatory muscle disease, allergic disease (e.g., allergic rhinitis), vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft-versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, multiple sclerosis, cystic fibrosis, chronic relapsing hepatitis, primary bil
- the compounds described herein are used as immunosuppressants to prevent transplant graft rejections, allogeneic or xenogeneic transplantation rejection (organ, bone marrow, stem cells, other cells and tissues), and graft-versus-host disease.
- transplant graft rejections result from tissue or organ transplants.
- graft-versus-host disease results from bone marrow or stem cell transplantation.
- One embodiment is a method of preventing or decreasing the risk of transplant graft rejection, allogeneic or xenogeneic transplantation rejection (organ, bone marrow, stem cells, other cells and tissues), or graft-versus-host disease by administering an effective amount of one or more compounds of the present invention.
- the compounds of the present invention are also useful in combination (administered together or sequentially) with known anti-cancer treatments, such as radiation therapy or with cytostatic, cytotoxic or anticancer agents, such as for example, but not limited to, DNA interactive agents, such as cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, docetaxel or the epothilones (for example ixabepilone), either naturally occurring or synthetic; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and anti-metabolites, such as methotrexate, other tyrosine kinase inhibitors such as Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDK inhibitors; SRC
- the compounds of the present invention are also useful in combination (administered together or sequentially) with one or more steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs (NSAIDs) or immune selective anti-inflammatory derivatives (ImSAIDs).
- NSAIDs non-steroidal anti-inflammatory drugs
- ImSAIDs immune selective anti-inflammatory derivatives
- the invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising one or more compounds of the present invention (such as a compound having formula (I), (IA), (IB), (IC), (ID), (IE), (II), (III), (IIIA), or (IIIB)) together with a pharmaceutically acceptable carrier.
- the pharmaceutical composition may further comprise one or more of the active ingredients identified above, such as other steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs (NSAIDs), immune selective anti-inflammatory derivatives (ImSAIDs) or anti-cancer agents.
- the pharmaceutical composition includes a therapeutically effective amount of one or more compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (II), (III), (IIIA), or (IIIB).
- Yet another embodiment is a method of treating autoimmune disorders in a patient in need thereof by administering a therapeutically effective amount of a compound of the present invention.
- the compounds of the present invention are effective for treating asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, psoriasis, lupus and experimental autoimmune encephalomyelitis (EAE).
- COPD chronic obstructive pulmonary disease
- EAE experimental autoimmune encephalomyelitis
- Yet another embodiment is a method of treating allergic rhinitis in a patient in need thereof by administering a therapeutically effective amount of a compound of the present invention.
- Yet another embodiment is a method of treating cancer in a patient in need thereof by administering a therapeutically effective amount of a compound of the present invention.
- the compounds of the present invention are effective for treating hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia.
- the compounds of the present invention are also effective for treating carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma, tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
- Yet another embodiment is a method of treating leukemia in a patient in need thereof by administering a therapeutically effective amount of a compound of the present invention.
- the compounds of the present invention are effective for treating chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), small lymphocytic lymphoma (SLL), and indolent non-Hodgkin's lymphoma (I-NHL).
- CLL chronic lymphocytic leukemia
- NHL non-Hodgkin lymphoma
- AML acute myeloid leukemia
- ALL acute lymphoblastic leukemia
- MM multiple myeloma
- SLL small lymphocytic lymphoma
- I-NHL indolent non-Hodgkin's lymphoma
- alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (t-butyl).
- C 1-3 alkyl refers to an alkyl group as defined above having up to 3 carbon atoms.
- C 1-6 alkyl refers to an alkyl group as defined above having up to 6 carbon atoms.
- the term “alkyl” refers to a hydrocarbon chain radical as mentioned above which is bivalent.
- alkenyl refers to an aliphatic hydrocarbon group containing one or more carbon-carbon double bonds and which may be a straight or branched or branched chain having about 2 to about 10 carbon atoms, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, and 2-butenyl.
- C 2-6 alkenyl refers to an alkenyl group as defined above having up to 6 carbon atoms. In appropriate circumstances, the term “alkenyl” refers to a hydrocarbon group as mentioned above which is bivalent.
- alkynyl refers to a straight or branched chain hydrocarbyl radical having at least one carbon-carbon triple bond, and having in the range of 2 to up to 12 carbon atoms (with radicals having in the range of 2 to up to 10 carbon atoms presently being preferred) e.g., ethynyl, propynyl, and butnyl.
- C 2-6 alkynyl refers to an alkynyl group as defined above having up to 6 carbon atoms.
- alkynyl refers to a hydrocarbyl radical as mentioned above which is bivalent.
- alkoxy unless otherwise specified, denotes an alkyl, cycloalkyl, or cycloalkylalkyl group as defined above attached via an oxygen linkage to the rest of the molecule.
- substituted alkoxy refers to an alkoxy group where the alkyl constituent is substituted (i.e., —O-(substituted alkyl).
- alkoxy refers to the group —O-alkyl, including from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, and cyclohexyloxy.
- alkoxy refers to a group as mentioned above which is bivalent.
- cycloalkyl denotes a non-aromatic mono or multicyclic ring system of about 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- multicyclic cycloalkyl groups include perhydronaphthyl, adamantyl and norbornyl groups, bridged cyclic groups, and sprirobicyclic groups, e.g., sprio (4,4) non-2-yl.
- C 3-6 cycloalkyl refers to a cycloalkyl group as defined above having up to 6 carbon atoms.
- C 3-10 cycloalkyl refers to a cycloalkyl group as defined above having from 3 to 10 carbon atoms.
- C 4-10 cycloalkyl refers to a cycloalkyl group as defined above having from 4 to 10 carbon atoms.
- cycloalkyl refers to a ring system as mentioned above which is bivalent.
- cycloalkylalkyl refers to a cyclic ring-containing radical containing in the range of about 3 up to 8 carbon atoms directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group, such as cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl.
- cycloalkenyl refers to cyclic ring-containing radicals containing in the range of about 3 up to 8 carbon atoms with at least one carbon-carbon double bond such as cyclopropenyl, cyclobutenyl, and cyclopentenyl.
- cycloalkenylalkyl refers to a cycloalkenyl group directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group.
- aryl refers to aromatic radicals having in the range of 6 up to 20 carbon atoms such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl.
- arylalkyl refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., —CH 2 C 6 H 5 and —C 2 H 5 C 6 H 5 .
- heterocyclic ring refers to a non-aromatic 3 to 15 member ring radical which consists of carbon atoms and at least one heteroatom selected from nitrogen, phosphorus, oxygen and sulfur.
- the heterocyclic ring radical may be a mono-, bi-, tri- or tetracyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
- the nitrogen atom may be optionally quaternized.
- the heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom.
- heterocyclyl refers to a heterocylic ring radical as defined above.
- the heterocylcyl ring radical may be attached to the main structure at any heteroatom or carbon atom.
- heterocyclylalkyl refers to a heterocylic ring radical as defined above directly bonded to an alkyl group.
- the heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group.
- heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-o-
- heteroaryl refers to an optionally substituted 5 to 14 member aromatic ring having one or more heteroatoms selected from N, O, and S as ring atoms.
- the heteroaryl may be a mono-, bi- or tricyclic ring system.
- heterocyclic ring or “heteroaryl” radicals include, but are not limited to, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, carbazolyl, quinolyl, isoquinolyl, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, qui
- heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom.
- substituted heteroaryl also includes ring systems substituted with one or more oxide (—O—) substituents, such as pyridinyl N-oxides.
- heteroarylalkyl refers to a heteroaryl ring radical as defined above directly bonded to an alkyl group.
- the heteroarylalkyl radical may be attached to the main structure at any carbon atom from alkyl group.
- cyclic ring refers to a cyclic ring containing 3 to 10 carbon atoms.
- substituted refers to substitution with any one or any combination of the following substituents which may be the same or different and are independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo ( ⁇ O), thio ( ⁇ S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted
- Substitution or the combinations of substituents envisioned by this invention are preferably those that result in the formation of a stable or chemically feasible compound.
- stable refers to the compounds or the structure that are not substantially altered when subjected to conditions to allow for their production, detection and preferably their recovery, purification and incorporation into a pharmaceutical composition.
- the substituents in the aforementioned “substituted” groups cannot be further substituted. For example, when the substituent on “substituted alkyl” is “substituted aryl”, the substituent on “substituted aryl” cannot be “substituted alkenyl”.
- halo means fluoro, chloro, bromo or iodo.
- haloalkyl haloalkenyl
- haloalkynyl haloalkoxy
- fluoroalkyl and fluoroalkoxy include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.
- protecting group refers to a substituent that is employed to block or protect a particular functionality. Other functional groups on the compound may remain reactive.
- an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, tert-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc).
- a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality.
- Suitable hydroxy-protecting groups include, but are not limited to, acetyl and silyl.
- a “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality.
- Suitable carboxy-protecting groups include, but are not limited to, —CH 2 CH 2 SO 2 Ph, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, and nitroethyl.
- protecting groups and their use see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
- Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the present chemical entities, pharmaceutical compositions and methods are meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures.
- Non-limiting examples of intermediate mixtures include a mixture of isomers in a ratio of 10:90, 13:87, 17:83, 20:80, or 22:78.
- Optically active (R)- and (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- tautomers refers to compounds, which are characterized by relatively easy interconversion of isomeric forms in equilibrium. These isomers are intended to be covered by this invention. “Tautomers” are structurally distinct isomers that interconvert by tautomerization. “Tautomerization” is a form of isomerization and includes prototropic or proton-shift tautomerization, which is considered a subset of acid-base chemistry. “Prototropic tautomerization” or “proton-shift tautomerization” involves the migration of a proton accompanied by changes in bond order, often the interchange of a single bond with an adjacent double bond. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached.
- keto-enol tautomerization An example of tautomerization is keto-enol tautomerization.
- keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers.
- phenol-keto tautomerization Another example of tautomerization is phenol-keto tautomerization.
- phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1H)-one tautomers.
- Conformational stereoisomers a form of stereoisomerism in which the isomers can be interconverted exclusively by rotations about formally single bonds.
- Such isomers are generally referred to as conformational isomers or conformers and may also be referred to as rotamers.
- the types of conformational isomers are related to the spatial orientations of the substituents between two vicinal atoms.
- Conformational isomerism includes ring conformation isomers such as cyclohexane conformations (chair and boat conformers) and cyclobutane “puckered” (or “butterfly”) conformations.
- “Atropisomers” refers to conformational stereoisomers which occur when rotation about a single bond in the molecule is prevented, or greatly slowed, as a result of steric interactions with other parts of the molecule and the substituents at both ends of the single bond are asymmetrical. Where the rotational barrier about the single bond is high enough, and interconversion between conformations is slow enough, separation and isolation of the isomeric species may be permitted. These isomers are intended to be covered by this invention.
- a “leaving group or atom” is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable examples of such groups unless otherwise specified are halogen atoms and mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups.
- prodrug refers to a compound, which is an inactive precursor of a compound, converted into its active form in the body by normal metabolic processes. Prodrug design is discussed generally in Hardma, et al. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 11-16 (1996). A thorough discussion is provided in Higuchi, et al., Prodrugs as Novel Delivery Systems, Vol. 14, ASCD Symposium Series, and in Roche (ed.), Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
- prodrugs can be converted into a pharmacologically active form through hydrolysis of, for example, an ester or amide linkage, thereby introducing or exposing a functional group on the resultant product.
- the prodrugs can be designed to react with an endogenous compound to form a water-soluble conjugate that further enhances the pharmacological properties of the compound, for example, increased circulatory half-life.
- prodrugs can be designed to undergo covalent modification on a functional group with, for example, glucuronic acid, sulfate, glutathione, amino acids, or acetate.
- the resulting conjugate can be inactivated and excreted in the urine, or rendered more potent than the parent compound.
- High molecular weight conjugates also can be excreted into the bile, subjected to enzymatic cleavage, and released back into circulation, thereby effectively increasing the biological half-life of the originally administered compound.
- ester refers to a compound, which is formed by reaction between an acid and an alcohol with elimination of water.
- An ester can be represented by the general formula RCOOR′.
- the instant invention also includes the compounds which differ only in the presence of one or more isotopically enriched atoms for example replacement of hydrogen with deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon.
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
- Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn; salts of organic bases such as N,N′-diacetylethylenediamine, glucamine, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine; chiral bases such as alkylphenylamine, glycinol, and phenyl glycinol; salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, omithine, lysine, arginine, and serine; quaternary ammonium salts of the compounds of invention with alkyl hal
- Salts may include acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides (e.g., hydrochlorides), acetates, tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates.
- acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides (e.g., hydrochlorides), acetates, tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates.
- AIDS Acquired Immuno Deficiency Syndrome
- HIV Human Immunodeficiency Virus
- Abbreviations used herein have their conventional meaning within the chemical and biological arts.
- cell proliferation refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.
- co-administration encompasses administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time.
- Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
- an effective amount refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below.
- the therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will induce a particular response in target cells, e.g. reduction of platelet adhesion and/or cell migration.
- the amount of compound administered ranges from about 0.1 mg to 5 g, from about 1 mg to 2.0 g, from about 100 mg to 1.5 g, from about 200 mg to 1.5 g, from about 400 mg to 1.5 g, and from about 400 mg to 1.0 g.
- treatment As used herein, “treatment,” “treating,” or “ameliorating” are used interchangeably. These terms refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
- therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
- a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
- the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
- a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- subject or “patient” refers to an animal, such as a mammal, for example a human.
- the methods described herein can be useful in both human therapeutics and veterinary applications (e.g., dogs, cats, cows, sheep, pigs, horses, goats, chickens, turkeys, ducks, and geese).
- the patient is a mammal, and in some embodiments, the patient is human.
- Radionuclides e.g., actinium and thorium radionuclides
- LET low linear energy transfer
- beta emitters conversion electron emitters
- high-energy radiation including without limitation x-rays, gamma rays, and neutrons.
- pharmaceutically acceptable excipient includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, one or more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorants/flavoring, carriers, buffers, stabilizers, solubilizers, and combinations thereof. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- Inflammatory response is characterized by redness, heat, swelling and pain (i.e., inflammation) and typically involves tissue injury or destruction.
- An inflammatory response is usually a localized, protective response elicited by injury or destruction of tissues, which serves to destroy, dilute or wall off (sequester) both the injurious agent and the injured tissue.
- Inflammatory responses are notably associated with the influx of leukocytes and/or leukocyte (e.g., neutrophil) chemotaxis.
- Inflammatory responses may result from infection with pathogenic organisms and viruses, noninfectious means such as trauma or reperfusion following myocardial infarction or stroke, immune responses to foreign antigens, and autoimmune diseases.
- Inflammatory responses amenable to treatment with the methods and compounds according to the invention encompass conditions associated with reactions of the specific defence system as well as conditions associated with reactions of the non-specific defence system.
- the therapeutic methods of the invention include methods for the amelioration of conditions associated with inflammatory cell activation.
- “Inflammatory cell activation” refers to the induction by a stimulus (including but not limited to, cytokines, antigens or auto-antibodies) of a proliferative cellular response, the production of soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive amines), or cell surface expression of new or increased numbers of mediators (including but not limited to, major histocompatibility antigens or cell adhesion molecules) in inflammatory cells (including but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes (polymorphonuclear leukocytes including neutrophils, basophils, and eosinophils) mast cells, dendritic cells, Langerhans cells, and endothelial cells). It will be appreciated by persons skilled in the art that the activation of one or a
- “Autoimmune disease” as used herein refers to any group of disorders in which tissue injury is associated with humoral or cell-mediated responses to the body's own constituents.
- Transplant rejection or “transplantation rejection” as used herein refers to any immune response directed against grafted tissue (including organs or cells (e.g., bone marrow), characterized by a loss of function of the grafted and surrounding tissues, pain, swelling, leukocytosis, and thrombocytopenia).
- Allergic disease as used herein refers to any symptoms, tissue damage, or loss of tissue function resulting from allergy.
- Article disease refers to any disease that is characterized by inflammatory lesions of the joints attributable to a variety of etiologies.
- Dermatis refers to any of a large family of diseases of the skin that are characterized by inflammation of the skin attributable to a variety of etiologies.
- the methods of the invention may be applied to cell populations in vivo or ex vivo.
- “In vivo” means within a living individual, as within an animal or human or in a subject's body. In this context, the methods of the invention may be used therapeutically or prophylactically in an individual.
- “Ex vivo” or “In vitro” means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including but not limited to fluid or tissue samples obtained from individuals. Such samples may be obtained by methods known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the invention may be used for a variety of purposes, including therapeutic and experimental purposes.
- the invention may be used ex vivo or in vitro to determine the optimal schedule and/or dosing of administration of a glutaminase inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental or diagnostic purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the invention may be suited are described below or will become apparent to those skilled in the art.
- the invention provides a pharmaceutical composition comprising one or more compounds of the present invention.
- the pharmaceutical composition may include one or more additional active ingredients as described herein.
- the pharmaceutical composition may be administered for any of the disorders described herein.
- compositions are typically formulated to provide a therapeutically effective amount of a compound of the present invention as the active ingredient.
- the pharmaceutical compositions contain a compound of the present invention as the active ingredient and one or more pharmaceutically acceptable carriers or excipients, such as inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions.
- the subject compounds and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.
- Methods include administration of a compound of the present invention by itself, or in combination as described herein, and in each case optionally including one or more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorants/flavoring, carriers, excipients, buffers, stabilizers, solubilizers, and combinations thereof.
- the compounds or pharmaceutical composition of the present invention can be administered by any route that enables delivery of the compounds to the site of action, such as oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical administration (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation.
- routes such as oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical administration (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation.
- the compounds can also be administered intraadiposally or intrathecally.
- compositions can be administered in solid, semi-solid, liquid or gaseous form, or may be in dried powder, such as lyophilized form.
- the pharmaceutical compositions can be packaged in forms convenient for delivery, including, for example, solid dosage forms such as capsules, sachets, cachets, gelatins, papers, tablets, capsules, suppositories, pellets, pills, troches, and lozenges.
- solid dosage forms such as capsules, sachets, cachets, gelatins, papers, tablets, capsules, suppositories, pellets, pills, troches, and lozenges.
- the type of packaging will generally depend on the desired route of administration.
- Implantable sustained release formulations are also contemplated, as are transdermal formulations.
- the invention also provides methods of using the compounds or pharmaceutical compositions of the present invention to treat disease conditions, including, but not limited to, diseases associated with overexpression of glutaminase and/or due to an excess of glutamine.
- the treatment methods provided herein comprise administering to the subject a therapeutically effective amount of a compound of the invention.
- the present invention provides a method of treating an inflammation disorder, including autoimmune diseases in a mammal. The method comprises administering to the mammal a therapeutically effective amount of a compound of the present invention.
- the treatment methods of the invention are useful in the fields of human medicine and veterinary medicine.
- the individual to be treated may be a mammal, preferably human, or other animal.
- individuals include but are not limited to farm animals including cows, sheep, pigs, horses, and goats; companion animals such as dogs and cats; exotic and/or zoo animals; laboratory animals including mice, rats, rabbits, guinea pigs, and hamsters; and poultry such as chickens, turkeys, ducks, and geese.
- the method of treating inflammatory or autoimmune diseases comprises administering to a subject (e.g. a mammal) a therapeutically effective amount of one or more compounds of the present invention that inhibits glutaminase.
- a subject e.g. a mammal
- glutaminase may inhibit inflammatory responses associated with inflammatory diseases, autoimmune disease, or diseases related to an undesirable immune response including but not limited to asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, psoriasis, lupus erythematosus, or graft versus host disease.
- Inhibition of glutaminase may further provide for a reduction in the inflammatory or undesirable immune response without a concomittant reduction in the ability to reduce a bacterial, viral, and/or fungal infection.
- the present invention provides methods of using the compounds or pharmaceutical compositions to treat respiratory diseases including but not limited to diseases affecting the lobes of lung, pleural cavity, bronchial tubes, trachea, upper respiratory tract, or the nerves and muscle for breathing.
- respiratory diseases including but not limited to diseases affecting the lobes of lung, pleural cavity, bronchial tubes, trachea, upper respiratory tract, or the nerves and muscle for breathing.
- methods are provided to treat obstructive pulmonary disease.
- COPD chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- Conditions included in this umbrella term include chronic bronchitis, emphysema, and bronchiectasis.
- the compounds described herein are used for the treatment of asthma.
- the compounds or pharmaceutical compositions described herein may be used for the treatment of endotoxemia and sepsis.
- the compounds or pharmaceutical compositions described herein are used to for the treatment of rheumatoid arthritis (RA).
- the compounds or pharmaceutical compositions described herein is used for the treatment of contact or atopic dermatitis.
- Contact dermatitis includes irritant dermatitis, phototoxic dermatitis, allergic dermatitis, photoallergic dermatitis, contact urticaria, systemic contact-type dermatitis and the like.
- Irritant dermatitis can occur when too much of a substance is used on the skin of when the skin is sensitive to certain substance.
- Atopic dermatitis sometimes called eczema, is a kind of dermatitis, an atopic skin disease.
- the invention also relates to a method of treating a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.
- said method relates to the treatment of cancer such as acute myeloid leukemia, thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related (e.g. lymphoma and Kaposi's sarcoma) or viral-induced cancer.
- cancer such as acute myeloid leukemia, thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian,
- said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
- a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
- the invention also relates to a method of treating diseases related to vasculogenesis or angiogenesis in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention.
- said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- Patients that can be treated with compounds of the present invention according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis; restenosis; atherosclerosis; BPH; breast cancer such as a ductal carcinoma in duct tissue in a mammary gland, medullary carcinomas, colloid carcinomas, tubular carcinomas, and inflammatory breast cancer; ovarian cancer, including epithelial ovarian tumors such as adenocarcinoma in the ovary and an adenocarcinoma that has migrated from the ovary into the abdominal cavity; uterine cancer; cervical cancer such as adenocarcinoma in the cervix epithelial including squamous cell carcinoma and adenocarcinomas; prostate cancer, such as a prostate cancer selected from the following: an adenocarcinoma or an adenocarinoma that has migrated to the bone; pancreatic cancer such as epitheliod carcinoma in the pancreatic duct tissue and
- the present invention provides methods of disrupting the function of a leukocyte or disrupting a function of an osteoclast.
- the method includes contacting the leukocyte or the osteoclast with a function disrupting amount of a compound of the invention.
- methods are provided for treating ophthalmic disease by administering one or more compounds or pharmaceutical compositions described herein to the eye of a subject.
- the invention further provides methods of inhibiting glutaminase by contacting a glutaminase with an amount of a compound of the invention sufficient to inhibit the activity of the glutaminase enzyme.
- the invention provides methods of inhibiting glutaminase enzyme activity by contacting a glutaminase enzyme with an amount of a compound of the invention sufficient to inhibit the activity of the glutaminase enzyme.
- the invention provides methods of inhibiting glutaminase enzyme activity. Such inhibition can take place in solution, in a cell expressing one or more glutaminase enzyme, in a tissue comprising a cell expressing the glutaminase, or in an organism expressing glutaminase.
- the invention provides methods of inhibiting glutaminase activity in an animal (including mammal such as humans) by contacting said animal with an amount of a compound of the invention sufficient to inhibit the activity of the glutaminase enzyme in said animal.
- Illustrative compounds of the present invention include those specified above in Table 1 and pharmaceutically acceptable salts thereof.
- the present invention should not be construed to be limited to only these compounds.
- the compounds of the present invention may be prepared by the following processes. Unless otherwise indicated, the variables (e.g. R 1 , R 2 , P, Q, A, B and L) when used in the below formulae are to be understood to present those groups described above in relation to any of formulas (I), (II) and (III) defined above. These methods can similarly be applied to other compounds of formulas (I), (IA), (IB), (IC), (ID), (IE), (II), (III), (IIIA) and (IIIB) as provided herein above with or without modification
- This scheme provides a method for the preparation of a compound of formula (I) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or —(CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 -, wherein L 2 is substituted or unsubstituted C 1-6 alkyl, L 1 and L 3 are absent or independently selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x , A is
- r is 0 or 1
- all the other variables including R x and R y ) are as described above in relation to formula (I).
- a compound of formula (12) can be coupled with a compound of formula (16) to form a compound of formula (17) under Sonogashira coupling reaction conditions in the presence of a palladium catalyst.
- the compound of formula (17) can be converted using zinc (Zn) and THF or using methods described in Knochel et al, Organozinc Reagents. A Practical Approach, Oxford University Press, 1999, to form a compound of formula (18).
- the compound of formula (18) can be coupled with a compound of formula (9) to form a compound of formula (19).
- the compound of formula (19) can be converted to form a compound of formula (14), which can be coupled with a compound of formula (15) to form the compound of formula (I). This scheme is illustrated by the example below.
- This scheme provides a method for the preparation of a compound of formula (I) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or —(CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 -, wherein L 2 is substituted or unsubstituted C 1-6 alkyl, L 1 and L 3 are absent or independently selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x , B is
- r is 0 or 1
- all the other variables including R x and R y ) are as described above in relation to formula (I).
- a compound of formula (15) can be converted to a compound of formula (6a), which can be coupled with a compound of formula (12a) to form a compound of formula (20) in the presence of N-methylpyrrolidone (NMP).
- NMP N-methylpyrrolidone
- the compound of formula (20) can be converted to a compound of formula (21) wherein r is 1, 2, 3 or 4 by, for example, reaction with BrZn(CH 3 ) n CN and NiCl 2 .
- the compound of formula (21) can be reacted with a compound of formula (2) to form a compound of formula (22), which can be can be coupled with a compound of formula (7) to form the compound of formula (I). This scheme is illustrated by the example below.
- This scheme provides a method for the preparation of a compound of formula (I) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or (CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 -, wherein L 2 is substituted or unsubstituted C 1-6 alkyl, L 1 and L 3 are absent or independently selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x , A is
- X is a leaving group such as bromine, r is 0 or 1, s is 0 or 1, and all the other variables (including R x and R y ) are as described above in relation to formula (I).
- the compound of formula (23) can be coupled with a compound of formula (8a) to form a compound of formula (9a), which can be coupled with a compound of formula (24), for example, in the presence of a suitable reagent such as a palladium catalyst to form a compound of formula (25).
- a suitable reagent such as a palladium catalyst
- the compound of formula (25) can be reduced to form a compound of formula (26).
- the compound of formula (26) can be reacted with a compound of formula (2) to form a compound of formula (14), which can be coupled with a compound of formula (27), for example, in the presence of suitable reagents such as HATU and N-ethyldiisopropyl amine to give the compound of formula (I).
- suitable reagents such as HATU and N-ethyldiisopropyl amine
- This scheme provides a method for the preparation of a compound of formula (I) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or —(CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 -, wherein L 2 is substituted or unsubstituted C 1-6 alkyl, L 1 and L 3 are absent or independently selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x , A is
- r is 0 or 1
- s is 0 or 1
- all the other variables including R x and R y ) are as described above in relation to formula (I).
- the compound of formula (25) can be reacted with a compound of formula (2) to form a compound of formula (28), which can be coupled with a compound of formula (27), for example, in the presence of suitable reagents such as HATU and N-ethyldiisopropyl amine to form a compound of formula (29).
- suitable reagents such as HATU and N-ethyldiisopropyl amine
- the compound of formula (29) can be reduced to form the compound of formula (I), for example, in the presence of suitable reagents, such as Pd(OH) 2 .
- suitable reagents such as Pd(OH) 2
- This scheme provides a method for the preparation of a compound of formula (I) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or —(CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 -, wherein L 2 is substituted or unsubstituted C 1-6 alkyl and L 1 and L 3 are absent or independently selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x , A is
- X is a leaving group such as bromine, r is 0 or 1, s is 0 or 1 and all the other variables (including R x and R y ) are as described above in relation to formula (I).
- the compound of formula (8a) can be coupled with a compound of formula (24), for example, in the presence of suitable reagents such as CuI and a palladium catalyst to form a compound of formula (30).
- suitable reagents such as CuI and a palladium catalyst
- the compound of formula (30) can be reduced to form a compound of formula (31), which can be coupled with a compound of formula (23), for example, in the presence of suitable reagents, such as HATU and DIPEA, to form a compound of formula (26).
- the compound of formula (I) can be prepared from a compound of formula (26) using the procedure described in Step-2 of Scheme 5 below. This scheme is illustrated by the example below.
- This scheme provides a method for the preparation of a compound of formula (I) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or —(CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 -, wherein L 2 is substituted or unsubstituted C 1-6 alkyl and L 1 and L 3 are absent or independently selected from O, S, —S( ⁇ O) q —, —C( ⁇ O)— and —NR x , A is
- r is 0 or 1
- s is 0 or 1
- the compound of formula (23) can be coupled with a compound of formula (8a) to form a compound of formula (9a).
- the compound of formula (9a) can be coupled with a compound of formula (32), for example, in the presence of suitable reagents, such as CuI and a palladium catalyst, to form a compound of formula (33).
- suitable reagents such as CuI and a palladium catalyst
- the compound of formula (33) can subsequently be deprotected to form a compound of formula (34).
- the compound of formula (34) can be treated with a suitable reagent, such as CuCl, to form a compound of formula (35), which can be reduced to form a compound of formula (I).
- a suitable reagent such as CuCl
- This scheme provides a method for the preparation of a compound of formula (III) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or —(CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 - wherein L 2 is substituted or unsubstituted C 4-10 cycloalkyl and L 1 and L 3 are absent or substituted or unsubstituted C 1-6 alkyl (such as methylene), B is
- X is leaving group such as bromine, r is 0 or 1, s is 0 or 1 and all the other variables (including R x and R y ) are as described above in relation to formula (III).
- the compound of formula (1) can be coupled with a compound of formula (m), for example, in the presence of suitable reagents such as K 2 CO 3 , xantphos and a palladium catalyst to form a compound of formula (n).
- suitable reagents such as K 2 CO 3 , xantphos and a palladium catalyst
- the compound of formula (n) can be coupled with a compound of formula (d), for example, in the presence of suitable reagents, such as HATU and DIPEA, to form a compound of formula (o), which can be reduced to form a compound of formula (i).
- the desired compound of formula (III) can be prepared from a compound of formula (i) by using the procedure described in Scheme-2A. This scheme is illustrated by the example below.
- This scheme provides a method for the preparation of a compound of formula (III) wherein R 1 and R 2 are independently substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, P and Q are independently —NR x C(O)—(CR x R y ) r —, or —(CR x R y ) r —CO—NR x —, L is -L 1 -L 2 -L 3 - wherein L 2 is substituted or unsubstituted C 4-10 cycloalkyl and L 1 and L 3 are absent or substituted or unsubstituted C 1-6 alkyl (such as methylene), B is
- X is leaving group such as bromine
- Pg is a protecting group
- r is 0 or 1
- s is 0 or 1 and all the other variables (including R x and R y ) are as described above in relation to formula (III).
- the compound formula (p1) wherein Pg is a protecting group such as benzyl can be reacted with CBr 4 to form a compound of formula (p).
- the compound of formula (p) can be coupled with a compound of formula (t), for example, in the presence of NiCl 2 and diethylzinc (DEZn), to form a compound of formula (q).
- the compound of formula (q) can be coupled with a compound of formula (d), for example, in the presence of suitable reagents, such as HATU and DIPEA, to form a compound of formula (r), which can be deprotected to form a compound of formula (s).
- the compound of formula (s) can be reacted with a compound of formula (b) in the presence of POCl 3 to form a compound of formula (j), which can be coupled with a compound of formula (k), for example, in the presence of suitable reagents, such as HATU and N-ethyldiisopropyl amine, to form a compound of formula (III).
- suitable reagents such as HATU and N-ethyldiisopropyl amine
- Example 1 (35 mg, 0.064 mmol) was dissolved in EtOAc (15 ml). To this mixture added Pd(OH) 2 and stirred under H 2 atmosphere (4 Kg Pressure) in an autoclave. Reaction mixture was filtered through cealite bed and bed was washed with EtOAc. EtOAc was removed on rotavapour to obtain crude. Crude was triturated with DCM and Petether mixture (1:1) to obtain the titled compound as an off-white solid.
- Example 33 50 mg, 0.06 mmol was dissolved in THF (7 ml) and added Et 2 O.HCl (2 ml). This mixture was stirred under nitrogen atmosphere for 2 h then removed THF and diethyl ether on rotavapour to obtain a residue. Residue was triturated with diethyl ether to obtain the titled compound (20 mg) as an off-white solid M.P.: 150-155° C.
- GAC Glutaminase 1
- a substrate solution is prepared (50 mM Tris-HCl pH 8.0, 0.2 mM EDTA, 150 mM K 2 HPO 4 , 0.1 mg/ml BSA, 1 mM DTT, 20 mM L-glutamine, 2 mM NAD + , and 10 ppm antifoam) and 50 ⁇ l of the substrate solution is to be added to a 96-well half area clear plate.
- the compound is added as a DMSO solution.
- Enzymatic reaction is started by the addition of 50 ⁇ l of enzyme solution (50 mM Tris-HCl pH 8.0, 0.2 mM EDTA, 150 mM K 2 HPO 4 , 0.1 mg/ml BSA, 1 mM DTT, 10 ppm antifoam, 4 units/ml GDH, 4 mM adenosine diphosphate, and 4 nM GAC) and read in a Molecular Devices M5 plate reader at 20° C.
- L-glutaminase enzyme assay can be performed using a colorimetric method by quantifying ammonia formation in a spectrophotometric analysis using Nessler's Reagent. The procedure is adopted from British Microbiology Research Journal, 4(1), 97-115, 2014, with modification.
- 0.1 ml of properly diluted enzyme (incubated with or without the test compound) is added to 0.4 ml of 0.025 M L-glutamine solution in 0.1 M boric acid borate buffer (pH 8.0). After incubation for 30 minutes at 37° C., the reaction is stopped by the addition of 0.5 ml of 1N H 2 SO 4 . The precipitated protein is removed by centrifugation and 0.2 ml of supernatant is added to 3.8 ml of distilled water. Thereafter, 0.5 ml of Nessler's reagent is added, and the absorbance measured at 400 nm within 1 to 3 minutes.
- Enzyme and substrate blanks are included in all assays, and a standard curve is prepared with ammonium chloride.
- the enzyme activity is expressed as unit (U)/ml.
- One unit of L-glutaminase is defined as the amount of enzyme that liberates one micromole ( ⁇ mol) of ammonia per minute under standard conditions.
- the specific activity (sp. activity) is defined as the units of L-glutaminase per milligram protein. Accordingly, the change in specific activity of glutaminase in the presence and absence of test compound is reported.
- Step 1 Preparation of Tissue Homogenates: Male Balb/c mice were administered 0.28 M ammonium chloride in drinking water for 7 days. The animals were sacrificed and brain/kidney organs collected on dry ice. These organs were suspended in a homogenization buffer containing 20 mM phosphate buffer—pH 7.4, 0.5 mM EDTA, 5 mM 2-mercaptoethanol, 25% glycerol and 0.02% BSA. The tissue was homogenized and supernatants were stored at ⁇ 80° C. until the enzyme assay was performed.
- Aim Compounds were assessed for their ability to inhibit the enzymatic activity of L-glutaminase present in mice brain/kidney homogenate.
- the assay was performed using a colorimetric method using Nessler's Reagent by quantifying the amount of ammonia formed as a by product during the enzymatic conversion of L-glutamine to glutamate.
- 16 ⁇ l of tissue homogenate is added to 33 ⁇ l of Tris-Hcl phosphate buffer (pH 8) along with 1 ⁇ l of DMSO/test compound containing the desired final concentration and vortexed briefly.
- 50 ⁇ l of 20 mM L-glutamine Tris buffer is added to start the reaction and incubated for 15 minutes at 37° C.
- the ammonia formed is detected by adding 20 ⁇ l of reaction mixture to cold water in a 96 well plate followed by 20 ⁇ l of Nessler's reagent. The colour developed is measured at 450 nm.
- Data Analysis Activity of the test compound is reported as % inhibition and the data is analyzed using Graphpad Prism (Graphpad software; San Diego Calif.) for IC 50 determination.
- Example 1 A C — Example 2 A B C Example 3 A B C Example-4 — D — Example-5 D D — Example-6 C D — Example-7 C D — Example-8 B C D Example-9 D D — Example-10 A A A Example-11 A A A Example-12 A A B Example-13 A A A Example-14 A A B Example-15 A B A Example-16 B C D Example-17 A C D Example-18 A B A Example-19 A B A Example-20 A A A Example-21 A B A Example-22 B D — Example-23 D D — Example-24 D D — Example-25 B D — Example-26 A B — Example-27 B D — Example-28 B A — Example-29 A B B Example-30 A B A Example-31 A B D Example-32 A D — Example-33 C D — Example-34 C D — Example-35 D D — Example-36 C C — Example-37 D D — Example-38 A C D Example
- Growth inhibition assays were carried out using 10% FBS supplemented media. Cells were seeded at a concentration of 5000-20,000 cells/well in a 96-well plate. Test compounds at a concentration range from 0.01 to 10000 nM were added after 24 hours. Growth was assessed using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MIT) dye reduction test at 0 h (prior to the addition of the test compound) and 72 hours after the addition of test compound. Absorbance was read on a Fluostar Optima (BMG Labtech, Germany) at a wave length of 450 nm. Data were analysed using GraphPad Prism and percent inhibition due to the test compound compared to the control was calculated accordingly. The results are as shown below.
- Example-109 A is ⁇ 100 nM; B is ⁇ 100 nM to ⁇ 400 nM; C is ⁇ 400 nM to ⁇ 1000 nM; D is ⁇ 1000 nM to ⁇ 5000 nM and E is ⁇ 5000 nM to ⁇ 10000 nM.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN36CH2014 | 2014-01-06 | ||
IN39/CHE/2014 | 2014-01-06 | ||
IN36/CHE/2014 | 2014-01-06 | ||
IN39CH2014 | 2014-01-06 | ||
IN2639CH2014 | 2014-05-29 | ||
IN2639/CHE/2014 | 2014-05-29 | ||
IN2647/CHE/2014 | 2014-05-29 | ||
IN2647CH2014 | 2014-05-29 | ||
IN2783CH2014 | 2014-06-06 | ||
IN2783/CHE/2014 | 2014-06-06 | ||
IN3525/CHE/2014 | 2014-07-18 | ||
IN3525CH2014 | 2014-07-18 | ||
IN3612CH2014 | 2014-07-24 | ||
IN3613/CHEN/2014 | 2014-07-24 | ||
IN3613CH2014 | 2014-07-24 | ||
IN3612/CHE/2014 | 2014-07-24 | ||
IN5438CH2014 | 2014-10-31 | ||
IN5438/CHE/2014 | 2014-10-31 | ||
PCT/IB2015/050076 WO2015101958A2 (en) | 2014-01-06 | 2015-01-05 | Novel inhibitors of glutaminase |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160297761A1 true US20160297761A1 (en) | 2016-10-13 |
Family
ID=52478027
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/769,331 Active US9783533B2 (en) | 2014-01-06 | 2015-01-05 | Glutaminase inhibitors |
US14/769,365 Abandoned US20160297761A1 (en) | 2014-01-06 | 2015-01-05 | Novel inhibitors of glutaminase |
US15/693,291 Expired - Fee Related US10611759B2 (en) | 2014-01-06 | 2017-08-31 | Glutaminase inhibitors |
US16/825,755 Abandoned US20210032236A1 (en) | 2014-01-06 | 2020-03-20 | Novel glutaminase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/769,331 Active US9783533B2 (en) | 2014-01-06 | 2015-01-05 | Glutaminase inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/693,291 Expired - Fee Related US10611759B2 (en) | 2014-01-06 | 2017-08-31 | Glutaminase inhibitors |
US16/825,755 Abandoned US20210032236A1 (en) | 2014-01-06 | 2020-03-20 | Novel glutaminase inhibitors |
Country Status (16)
Country | Link |
---|---|
US (4) | US9783533B2 (pt) |
EP (2) | EP3092236B1 (pt) |
JP (3) | JP6666263B2 (pt) |
KR (3) | KR20220013017A (pt) |
CN (5) | CN105960405B (pt) |
AU (1) | AU2015204210B2 (pt) |
BR (1) | BR112016015706A8 (pt) |
CA (2) | CA2934700A1 (pt) |
CL (1) | CL2016001715A1 (pt) |
DK (1) | DK3092236T3 (pt) |
EA (3) | EA201991183A1 (pt) |
ES (1) | ES2833576T3 (pt) |
IL (1) | IL246362B (pt) |
SG (1) | SG11201605478XA (pt) |
WO (2) | WO2015101958A2 (pt) |
ZA (1) | ZA201604272B (pt) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10125130B2 (en) | 2014-04-30 | 2018-11-13 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
US11254666B2 (en) | 2017-06-13 | 2022-02-22 | Medshine Discovery Inc. | Compound as GLS1 inhibitor |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2761951T3 (es) | 2012-11-21 | 2020-05-21 | Agios Pharmaceuticals Inc | Inhibidores de glutaminasa y métodos de uso |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
EP3092236B1 (en) * | 2014-01-06 | 2020-08-26 | Rhizen Pharmaceuticals S.A. | Novel glutaminase inhibitors |
BR112016021620A2 (pt) * | 2014-03-21 | 2018-07-10 | Agios Pharmaceuticals Inc | compostos e seus métodos de uso |
US9809588B2 (en) | 2014-07-03 | 2017-11-07 | Board Of Regents, The University Of Texas System | GLS1 inhibitors for treating disease |
US10660861B2 (en) | 2014-07-09 | 2020-05-26 | The Johns Hopkins University | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy |
WO2017004359A1 (en) * | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
US10842763B2 (en) | 2015-07-31 | 2020-11-24 | The Johns Hopkins University | Methods for cancer and immunotherapy using prodrugs of glutamine analogs |
CN108348492B (zh) * | 2015-07-31 | 2021-09-28 | 约翰霍普金斯大学 | 使用谷氨酰胺类似物的用于癌症和免疫疗法的方法 |
MX2018001300A (es) | 2015-07-31 | 2019-03-14 | Univ Johns Hopkins | Profarmacos de analogos de glutamina. |
WO2017021177A1 (en) * | 2015-08-04 | 2017-02-09 | Universitat De Barcelona | Pharmaceutical combinations for use in the treatment of cancer |
GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
TW201733587A (zh) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
US10040789B2 (en) | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
BR112018012701A2 (pt) | 2015-12-21 | 2018-12-04 | Council Scient Ind Res | novos compostos de 1,2,3 triazol-tiazol, processo para preparação e utilização dos mesmos |
CA3009355A1 (en) | 2015-12-22 | 2017-06-29 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
CN107474024B (zh) * | 2016-06-08 | 2022-12-13 | 北京赛林泰医药技术有限公司 | 一种谷氨酰酶抑制剂及其组合物和用途 |
WO2018102715A1 (en) * | 2016-12-02 | 2018-06-07 | Indiana University Research And Technology Corporation | Compositions and methods for treating and/or reducing corneal dystrophy |
RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
SG10202011632RA (en) | 2017-10-27 | 2021-01-28 | Boehringer Ingelheim Int | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors |
US20190269705A1 (en) * | 2017-11-27 | 2019-09-05 | Regents Of The University Of Minnesota | Methods and materials for treating graft versus host disease |
EP3829716B1 (en) * | 2018-07-31 | 2023-02-01 | Eli Lilly and Company | 5-methyl-4-fluoro-thiazol-2-yl compounds |
WO2020095971A1 (ja) * | 2018-11-08 | 2020-05-14 | 国立大学法人東京大学 | 老化細胞を除去する方法、および老化細胞の調製方法 |
CN109223778B (zh) * | 2018-11-16 | 2021-07-27 | 上海市肺科医院 | C24h24n6o2s3在制备抗结核菌药物中的用途 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11958818B2 (en) | 2019-05-01 | 2024-04-16 | Boehringer Ingelheim International Gmbh | (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
CN111643669A (zh) * | 2020-06-30 | 2020-09-11 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 谷氨酰胺酶抑制剂在制备治疗银屑病的药物中的应用 |
WO2022266162A1 (en) | 2021-06-16 | 2022-12-22 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
CN114805346A (zh) * | 2021-07-08 | 2022-07-29 | 成都硕德药业有限公司 | 杂环类衍生物、其制备方法及用途 |
CN116023375A (zh) * | 2021-10-25 | 2023-04-28 | 成都苑东生物制药股份有限公司 | 一种杂环类衍生物、其制备方法及用途 |
WO2023212718A2 (en) * | 2022-04-29 | 2023-11-02 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
CN114874186B (zh) * | 2022-05-16 | 2023-07-11 | 深圳大学 | 一种谷氨酰胺酰基环化酶同工酶抑制剂及其制备方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015166373A1 (en) * | 2014-04-30 | 2015-11-05 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2104783A1 (en) * | 1970-07-14 | 1972-04-21 | Berlin Chemie Veb | 2,5-disubstd 2-amino-1,3,4-thiadiazoles-from 4-substd 1-acylthiosemic - virustatics |
JPH0358980A (ja) * | 1989-07-28 | 1991-03-14 | Canon Inc | 液晶性化合物、これを含む液晶組成物、およびこれを使用した液晶素子 |
EP0656210A1 (en) | 1993-11-19 | 1995-06-07 | Takeda Chemical Industries, Ltd. | Imidazole derivatives as glutaminose inhibitors |
US6310093B1 (en) | 1997-08-29 | 2001-10-30 | Elan Pharmaceuticals, Inc. | Method of preventing neuronal death |
EP1181045A4 (en) | 1999-04-02 | 2003-04-23 | Los Angeles Childrens Hospital | USE OF ASPARAGINASE AND GLUTAMINASE TO TREAT AUTOIMMUNE DISEASES OR DISEASES CAUSED BY GRAFT REJECTION |
US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
NO315152B1 (no) | 2001-06-28 | 2003-07-21 | Tomm Slater | Anordning for rensing av luft |
EP1434576A4 (en) | 2001-09-13 | 2006-03-29 | Kenneth E Miller | METHOD FOR RELIEVING PAIN |
SE0300456D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
EP1597256A1 (en) * | 2003-02-21 | 2005-11-23 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
DE10326821A1 (de) | 2003-06-11 | 2005-01-05 | Medical Enzymes Ag | Pharmazeutische Kombinationspräparate zur Krebstherapie |
WO2007001395A2 (en) | 2004-10-04 | 2007-01-04 | University Of South Carolina | Prevention and treatment of influenza with glutamine antagonist agents |
BRPI0616839A2 (pt) | 2005-10-06 | 2013-01-01 | Nippon Soda Co | agentes para controle de praga, e, compostos de amina cìclicos |
EP2015743B1 (de) | 2006-05-10 | 2016-08-17 | New Medical Enzymes AG | Glutadon |
TW200819437A (en) * | 2006-08-17 | 2008-05-01 | Astrazeneca Ab | Chemical compounds |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
TWI414523B (zh) * | 2006-12-28 | 2013-11-11 | Metabolex Inc | 用於治療糖尿病及代謝病症之雜環受體促效劑 |
BRPI0814294A2 (pt) | 2007-07-19 | 2015-02-03 | Metabolex Inc | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. |
WO2009126535A1 (en) * | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
US20110112103A1 (en) * | 2008-04-22 | 2011-05-12 | Daiichi Sankyo Company, Limited | 5-hydroxypyrimidine-4-carboxamide compound |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
JPWO2010013849A1 (ja) | 2008-08-01 | 2012-01-12 | 日本ケミファ株式会社 | Gpr119作動薬 |
WO2010033871A2 (en) | 2008-09-18 | 2010-03-25 | The Johns Hopkins University | Compositions and methods targeting glutaminase |
EP2350067A2 (en) * | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
WO2010048149A2 (en) * | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
JP2010138082A (ja) * | 2008-12-09 | 2010-06-24 | Nippon Soda Co Ltd | 環状アミン化合物またはその塩、並びに有害生物防除剤 |
WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
JPWO2011025006A1 (ja) | 2009-08-31 | 2013-01-31 | 日本ケミファ株式会社 | Gpr119作動薬 |
KR102012398B1 (ko) * | 2009-11-05 | 2019-08-20 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 벤조피란 키나제 조절제 |
ES2362770B1 (es) | 2009-12-24 | 2012-05-22 | Universidad De Sevilla | Uso de compuesto n-fenil-n'-(3-metil-2-butenil)tiourea para la elaboración de medicamentos destinados al tratamiento de la encefalopatía hepática. |
KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Gpr119 작동약 |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
DK2571878T3 (en) * | 2010-05-17 | 2019-02-11 | Indian Incozen Therapeutics Pvt Ltd | Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
US20130252983A1 (en) | 2010-09-10 | 2013-09-26 | Cornell University | Activating phosphorylation site on glutaminase c |
JP2014094886A (ja) * | 2011-02-28 | 2014-05-22 | Nippon Chemiphar Co Ltd | Gpr119作動薬 |
CN103030597B (zh) | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途 |
TW201321353A (zh) | 2011-10-08 | 2013-06-01 | Novartis Ag | 胺基甲酸酯/尿素衍生物 |
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
BR112014012129A8 (pt) * | 2011-11-21 | 2017-06-20 | Calithera Biosciences Inc | inibidores heterocíclicos de glutaminase |
WO2014043633A1 (en) | 2012-09-17 | 2014-03-20 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
KR102220175B1 (ko) | 2012-11-16 | 2021-02-24 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 헤테로사이클릭 글루타미나아제 억제제 |
ES2761951T3 (es) | 2012-11-21 | 2020-05-21 | Agios Pharmaceuticals Inc | Inhibidores de glutaminasa y métodos de uso |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
CN105283182A (zh) | 2012-12-03 | 2016-01-27 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶的杂环抑制剂治疗癌症 |
EP3092236B1 (en) * | 2014-01-06 | 2020-08-26 | Rhizen Pharmaceuticals S.A. | Novel glutaminase inhibitors |
-
2015
- 2015-01-05 EP EP15705845.4A patent/EP3092236B1/en active Active
- 2015-01-05 DK DK15705845.4T patent/DK3092236T3/da active
- 2015-01-05 CN CN201580006698.0A patent/CN105960405B/zh not_active Expired - Fee Related
- 2015-01-05 EA EA201991183A patent/EA201991183A1/ru unknown
- 2015-01-05 CN CN201580009614.9A patent/CN106029659B/zh not_active Expired - Fee Related
- 2015-01-05 JP JP2016562079A patent/JP6666263B2/ja not_active Expired - Fee Related
- 2015-01-05 KR KR1020227001963A patent/KR20220013017A/ko not_active Application Discontinuation
- 2015-01-05 JP JP2016562078A patent/JP6783663B2/ja active Active
- 2015-01-05 WO PCT/IB2015/050076 patent/WO2015101958A2/en active Application Filing
- 2015-01-05 WO PCT/IB2015/050075 patent/WO2015101957A2/en active Application Filing
- 2015-01-05 CN CN202010256915.4A patent/CN111393431A/zh active Pending
- 2015-01-05 EA EA201691135A patent/EA033163B1/ru unknown
- 2015-01-05 CA CA2934700A patent/CA2934700A1/en not_active Abandoned
- 2015-01-05 SG SG11201605478XA patent/SG11201605478XA/en unknown
- 2015-01-05 BR BR112016015706A patent/BR112016015706A8/pt not_active Application Discontinuation
- 2015-01-05 US US14/769,331 patent/US9783533B2/en active Active
- 2015-01-05 KR KR1020167021582A patent/KR20160100408A/ko not_active Application Discontinuation
- 2015-01-05 CN CN202010671865.6A patent/CN111892589A/zh active Pending
- 2015-01-05 ES ES15705845T patent/ES2833576T3/es active Active
- 2015-01-05 EA EA201691134A patent/EA035499B1/ru unknown
- 2015-01-05 US US14/769,365 patent/US20160297761A1/en not_active Abandoned
- 2015-01-05 AU AU2015204210A patent/AU2015204210B2/en not_active Ceased
- 2015-01-05 CN CN202110114920.6A patent/CN112920180A/zh active Pending
- 2015-01-05 CA CA2934702A patent/CA2934702A1/en not_active Abandoned
- 2015-01-05 EP EP15705095.6A patent/EP3092235A2/en not_active Withdrawn
- 2015-01-05 KR KR1020167021580A patent/KR20160100407A/ko not_active Application Discontinuation
-
2016
- 2016-06-21 IL IL246362A patent/IL246362B/en unknown
- 2016-06-23 ZA ZA2016/04272A patent/ZA201604272B/en unknown
- 2016-07-05 CL CL2016001715A patent/CL2016001715A1/es unknown
-
2017
- 2017-08-31 US US15/693,291 patent/US10611759B2/en not_active Expired - Fee Related
-
2019
- 2019-05-13 JP JP2019090711A patent/JP2019163290A/ja active Pending
-
2020
- 2020-03-20 US US16/825,755 patent/US20210032236A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015166373A1 (en) * | 2014-04-30 | 2015-11-05 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
Non-Patent Citations (15)
Title |
---|
"Psoriasis." (Mar 25, 2011). Accessed December 8, 2018. Available from: < https://www.aad.org/public/diseases/scaly-skin/psoriasis/psoriasis >. (Year: 2011) * |
American Cancer Society. "Breast Cancer." (2014), Accessed 9 November 2018. Available from: < https://www.cancer.org/cancer/breast-cancer/risk-and-prevention.html >. (Year: 2014) * |
American Cancer Society. "Treating Squamous Cell Carcinoma of the Skin." (2018). Accessed 8 December 2018. Available from: < https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer/treating/squamousl-cell-carcinoma.html >. (Year: 2018) * |
Ettmayer, P., et al. "Lessons Learned from Marketed and Investigational Prodrugs." J. Med. Chem. (2004) 47(10), pages 2393-2404. * |
Han, H. "Targeted Prodrug Design to Optimize Drug Delivery." AAPS Pharmsci. (2000), Vol. 2 (1) article 6, pp. 1-11. * |
Hirshberg Foundation for Pancreatic Cancer Research. "Prognosis." (2001). Accessed 8 December 2018. Available from: < http://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/ >. (Year: 2001) * |
Mayo Clinic. "Heart Transplant." (2018). Accessed December 8, 2018. Available from: < https://www.mayoclinic.org/tests-procedures/heart-transplant/about/pac-20384750 >. (Year: 2018) * |
National Cancer Institute. "Cancer Types by Site." (Mar 14, 2011). Accessed December 8, 2018. Available from: < https://web.archive.org/web/20110314030905/https://training.seer.cancer.gov/disease/categories/site.html >. (Year: 2011) * |
NavigatingCancer.com. "List of Cancer Chemotherapy Drugs." (2013). Accessed 9 November 2018. Available from: < https://www.navigatingcare.com/library/all/chemotherapy_drugs >. (Year: 2013) * |
Parlati, F., et al. "A Novel Pharmacodynamic Assay to Measure Glutaminase Inhibition Following Oral Administration of CB-839 in Triple Negative Breast Cancer Biopsies." Calithera Biosciences. (December 9, 2014). (Year: 2014) * |
Parlati, F., et al. "Glutaminase Inhibitor CB-839 Synergizes with Pomalidomide in Preclinical Multiple Myeloma Models." Calithera Biosciences. (December 6, 2014). Poster presentation San Francisco, CA December 6-9, 2014. (Year: 2014) * |
Parlati, F., et al. "Novel Pharmacodynamic Assays to Measure Glutaminase Inhibition Following Oral Administration of CB-839." Calithera Biosciences. (October 2014). (Year: 2014) * |
Rahman, T., et al. "The difficulties in cancer treatment." ecancermedicalscience. (November 2012). (Year: 2012) * |
Slusher, B.S., et al. "Small Molecule Glutaminase Inhibitors Block Glutamate Release from Stimulated Microglia." Biochem Biophys Res Commun. (Jan 3, 2014), Vol. 443, Issue 1, pp. 32-36. (Year: 2014) * |
Testa, B. "Prodrug research: futile or fertile?" Biochem. Pharm. (2004) 68, pages 2097-2106. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10125130B2 (en) | 2014-04-30 | 2018-11-13 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
US10676471B2 (en) | 2014-04-30 | 2020-06-09 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
US11254666B2 (en) | 2017-06-13 | 2022-02-22 | Medshine Discovery Inc. | Compound as GLS1 inhibitor |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10611759B2 (en) | Glutaminase inhibitors | |
US11465981B2 (en) | Heterocyclic compounds as immunomodulators | |
US10703746B2 (en) | Mutant IDH1 inhibitors useful for treating cancer | |
US10308615B2 (en) | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | |
CN107428765B (zh) | 用作irak抑制剂的哒嗪酮类大环化合物及其用途 | |
US20180273519A1 (en) | Heterocyclic compounds as immunomodulators | |
WO2014159690A1 (en) | Dna-pk inhibitors | |
CA2735779A1 (en) | Bicyclic kinase inhibitors | |
CN110997657A (zh) | 咪唑烷化合物 | |
TW202241871A (zh) | Cdk抑制劑 | |
JP2022505872A (ja) | アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体 | |
US20140038991A1 (en) | Protein Kinase Inhibitors | |
US20240067645A1 (en) | Heterocyclic compound as diacylglycerol kinase inhibitor and use thereof | |
CN118055926A (zh) | Rock2抑制剂及其用途 | |
CN116063325A (zh) | 具有btk调节作用的大环化合物及其用途 | |
OA20225A (en) | Baron containing PDE4 inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RHIZEN PHARMACEUTICALS SA, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BHAVAR, PRASHANT K;VAKKALANKA, SWAROOP K;VISWANADHA, SRIKANT;AND OTHERS;SIGNING DATES FROM 20150929 TO 20150930;REEL/FRAME:036824/0057 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: RHIZEN PHARMACEUTICALS SA, SWITZERLAND Free format text: CHANGE OF ADDRESS;ASSIGNOR:RHIZEN PHARMACEUTICALS SA;REEL/FRAME:056775/0375 Effective date: 20201208 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: RHIZEN PHARMACEUTICALS AG, SWITZERLAND Free format text: CHANGE OF ADDRESS;ASSIGNOR:RHIZEN PHARMACEUTICALS AG;REEL/FRAME:057836/0286 Effective date: 20210914 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |